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Because of the long history of the use of formalin as the standard fixative 
for tissue processing in histopathology, these archival formalin-fixed and paraffin-
embedded (FFPE) tissues present invaluable resources for conducting retrospective 
disease investigations. However, the high degree of covalently cross-linked proteins 
in FFPE tissues hinders efficient extraction of proteins from tissue sections and 
prevents subsequent proteomics efforts from opening the door to a veritable treasure 
trove of information sequestered in archival tissues.  
To this end, a protein extraction methodology has been optimized and 
demonstrated to achieve effective protein extraction together with combined 
technological development for enabling comprehensive and comparative proteome 
studies across archival FFPE tissue collections. An effective discovery-based 
proteome platform combining capillary isoelectric focusing (CIEF)-based 
  
multidimensional separation system with electrospray ionization-mass spectrometry 
(ESI-MS) has been developed to enable ultrasensitive analysis of minute protein 
amounts extracted from targeted cells in tissue specimens in this thesis.  
Based on our initial success in analyzing protein profiles within 
microdissected FFPE tissues, this project further demonstrates the ability to achieve 
high confidence and comparative proteomic analysis using tissue blocks stored for as 
many as 28 years. Vacuolar proton translocating ATPase 116 kDa subunit isoform a3, 
one of the unique proteins expressed in the ASPS, is further validated by 
immunohistochemistry (IHC). Although IHC is highly sensitive and provides the 
subcellular resolution, MS-based proteome profiling enables global identification and 
quantification of thousands of proteins without a prior knowledge of individual 
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1.1          BIOMARKER DISCOVERY VIA TISSUE PROTEOMICS 
A biological marker, biomarker, is defined as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathological processes, or pharmacological responses to a therapeutic 
intervention”[1]. Biomarkers can be categorized into three major classes including 
diagnostic, prognostic, and predictive markers. Even though routine cancer diagnosis 
is largely based on microscopical assessments of morphologic alternations of cells 
and tissues[2], diagnostic markers can be used to aid histopathological tumor 
classification which is critical for optimal treatment choices. Prognostic markers 
provide information regarding the malignant potential of tumors. Predictive markers 
are employed to choose between different alternative treatments modalities. For 
example, validated predictive factors for breast cancer patients include the assessment 




receptor 2[3]. Assay of HER-2/neu is now mandatory in deciding which patients with 
metastatic breast cancer should receive treatment with the monoclonal antibody, 
Herceptin[4]. 
Predictions of cancer behavior and likely drug response have been 
confounded by the great complexity of the human genome and, very often, the 
cellular heterogeneity of tumors. While analyses of DNA and RNA expression 
profiles through techniques including cDNA microarrays, comparative genomic 
hybridization, loss of heterozygosity, and single nucleotide polymorphism (SNP) 
analysis are important in identifying genetic abnormalities and uncovering the 
molecular dysfunctions existing in tumor cells, the presence of SNPs, changes in 
DNA copy numbers, or altered RNA levels may have little or no effect on the events 
actually happening at the protein level. For example, although 62 genes or more are 
possibly associated with the onset, progression, and/or severity of breast cancer[5], 
the specific roles played by the majority of these genes are yet to be clearly elucidated 
at the protein level, and only a small number have been clinically validated or 
associated with clinical phenotype. Besides the lack of understanding of the 
information encoded in the DNA sequence to identify the complete set of open-
reading frames, protein diversity is further complicated and multiplied through 
alternative splicing and chemical/enzymatic modifications.   
Thus, there is an urgent need for the development of technologies that allow the 
monitoring of protein expression and processing in tumor tissues resulting from 
development, physiology, and disease state. The ability to monitor the presence or absence 




post-translational modifications (PTMs), or combination of these variations in protein 
profiles will provide a more accurate snapshot of the molecular basis of a cancer lesion 
due to a systematic understanding of the multiple components of complex cellular 
networks driving differentiation and proliferation. For example, the transformation of a 
normal cell into a cancer cell requires multiple genetic modifications or changes, such as 
alterations in the cell cycle specifically modulating protein modifications or mechanisms 
of DNA repair. The identification of gene products either distinctive to cancers, or playing 
a possible role related to their development, will help define the sequence of molecular 
events that lead to cancer. As the efforts in tissue proteomics-based biomarker discovery 
progress, a profound impact will be made directly on disease related research ranging 
from the ability to enhance early detection and diagnosis of disease to the identification of 
biologically relevant targets for drug development and screening. 
1.2         TWO-DIMENSIONAL GEL ELECTROPHORESIS-BASED TISSUE 
PROTEOMICS 
Determinations of the levels or activities of specific analytes in tissue biopsies, 
used as biomarkers to detect, diagnose or evaluate prognosis of a patient, are typically 
performed biochemically or by IHC[6, 7]. If the analyte is measured biochemically, a 
tissue specimen consisting of a heterogeneous cell population is homogenized and the 
final concentration of the analyte from the diseased cells is “diluted” by the contribution of 
other proteins released from non-diseased cells (e.g. normal epithelium and stromal cells). 
Therefore, an under-estimate of the analyte concentration is likely to be observed, 
complicating the appropriate cut-off value between disease and normal states. While some 




cancer patients well, e.g. estrogen receptors in the selection of tamoxifen-responsive breast 
cancer[7], many questions of analyte expression in cancer remain. As reviewed by Cole et 
al.[8], collection and processing of human tissue biopsies primarily serve a clinical 
purpose (diagnosis, staging) with little emphasis on sampling and preservation for 
sophisticated genomic and proteomic analyses. Complicating these issues is the obvious 
problem of cell heterogeneity in the tissue section, which often results in misleading or 
confusing molecular findings[8, 9].        
Still, biologically relevant proteomics data can only be generated if the 
samples investigated consist of homogeneous cell populations, in which no unwanted 
cells of different types and/or development stages obscure the results. One of the 
main problems with the analysis of tissue proteomics is the heterogeneous nature of 
the sample. As shown in (Fig. 1-1), many different cell types are typically present in 
tissue biopsies, and in the case of diseased tissue small numbers of abnormal cells 
may lie within or adjacent to unaffected areas. Thus, several tissue microdissection 
technologies, including laser capture microdissection (LCM) [10, 11], laser 
microdissection [12], and laser-free microdissection[13, 14], have been developed to 
provide a rapid and straightforward method for procuring homogeneous 
subpopulations of cells or structures for biochemical and molecular biological 
analyses. It should be noted that the use of laser for tissue preparation in LCM [10, 11] 
and laser microdissection [12] may subject samples to potential processing-induced 
changes at two different stages: first during the staining of tissue sections to enable 
































These changes further impact the level of protein recovery as the result of sample 
alterations and the quality of subsequent proteome studies. 
Current protein analysis technologies are still largely based upon two-
dimensional polyacrylamide gel electrophoresis (2-D PAGE), which is central to much of 
what is now described as “proteomics”. This is due to its ability to provide detailed views 
of thousands of proteins expressed by an organism or cell type. However, in the absence 
of protein amplification techniques, proteomic analysis of microdissection-procured 
specimens is severely constrained by sample amounts ranging from 103-105 cells, 
corresponding to a total protein content of 0.1-10 µg[11]. While limited 2-D PAGE 
analyses of microdissection-derived tissue samples have been attempted[16-22], these 
studies involve significant manual effort and time to extract sufficient amounts of protein 
for obtaining gel patterns of good visual quality (Fig. 1-2), while providing little proteome 
information beyond a relatively small number of high abundance protein identifications. 
In addition, the 2-D PAGE-MS approach itself suffers from low throughput and poor 

















Figure 1-2          The 2-D PAGE protein expression pattern of GBM procured by the  









1.3         TISSUE PROTEIN PROFILING USING MATRIX-ASSISTED LASER 
DESORPTION/IONIZATION MASS SPECTROMETRY 
Cells isolated and captured by tissue microdissection techniques have been 
directly analyzed using matrix-assisted laser desorption/ionization mass spectrometry 
(MALDI-MS)[23-25]. The m/z signals or peaks obtained from MALDI-MS are correlated 
with protein distribution within a specific region of the tissue sample and can be used to 
construct ion density maps or specific molecular images for virtually every signal detected 
in the analysis. Similarly, surface-enhanced laser desorption/ionization-mass spectrometry 
(SELDI-MS) has been reported as a relatively simple, rapid, and sensitive protein 
biomarker analysis tool with potential clinical utility[26-31]. Although SELDI-MS 
spectral peaks do not provide protein identifications, the resulting fingerprint patterns have 
been explored for diagnostic applications including the early detection of several types of 
cancers. However, reproducibility of sample preparation and mass spectra among different 
laboratories has been problematic for both methodological and biological reasons, and 
little physical or biological meaning can be attributed to the spectral peaks which are 
clustered only in the low m/z region[29]. 
While SELDI has been shown to produce observable MS profiles with as few as 
25-50 cells, the transition of protein pattern produced by SEIDI to protein identity is 
generally quite difficult. The efforts typically involve tracking the specific peak of interest 
through a number of chromatography and gel purification steps to ensure that the peptides 
measured in the proteolytic digest are mainly derived from the protein of interest[32]. The 
inherent large-scale and the difficulty of this protein identification process not only 




identification of highly abundant proteins, but also call into question the practicality of 
overall SELDI approach when working with limited clinical samples in general, and 
microdissected tissue specimens in particular.  
1.4    CAPILLARY SEPARATIONS FOR TISSUE PROTEOMICS 
1.4.1 Multidimensional Liquid Chromatography Systems 
Yates and co-workers[33]demonstrated the use of shotgun identification of 
protein mixtures by proteolytic digestion followed with multidimensional liquid 
chromatography and tandem MS to separate and fragment the resulting peptides. Total 
peak capacity improvements in multidimensional chromatography platforms have 
increased the number of detected peptides and proteins identified due to better use of the 
MS dynamic range and reduced discrimination during ionization. To increase the 
proteome coverage, particularly for the identification of low abundance proteins, these 
peptide-based proteome technologies often require large quantities of 
enzymatically/chemically cleaved peptides, ranging from a few mgs[34, 35]to several 
hundred µgs[33, 36, 37], and are generally incompatible with protein levels extracted from 
microdissection-procured tissue samples.  
Thus, the reported tissue proteomic studies employing multidimensional liquid 
chromatography separations [38-41] are mainly based on the analysis of entire tissue 
sections instead of subpopulations of microdissection-derived tumor cells. The minimal 
quantity of available sample from targeted tumor cells has restricted analysis to the use of 
only a single chromatography separation prior to tandem MS analysis in recent studies 
[42-45] and limited the ability for mining deeper into the tissue proteome. Since the sizes 




diagnosis, a more effective discovery-based proteome technology is critically needed to 
enable sensitive studies of protein profiles within tissue specimens procured by 
microdissection techniques[10-14].      
   1.4.2 CIEF-Based Multidimensional Separations 
An effective discovery-based proteome platform[15, 46, 47], which combines 
CIEF with nano-reversed phase liquid chromatography (nano-RPLC) (Fig. 1-3), has 
recently been developed to enable ultrasensitive analysis of minute protein amounts 
extracted from small cell populations and limited tissue samples. As demonstrated in our 
previous studies[15, 46, 47], the key to establishing ultrasensitive proteome analysis is 
attributed to high analyte concentrations in small peak volumes as the result of 
electrokinetic focusing/stacking and high resolving multidimensional separation 
techniques, thereby enhancing the dynamic range and detection sensitivity of MS 
measurements. Furthermore, a key feature of CIEF-based proteome technology is the 
elimination of analyte loss and dilution in an integrated platform while achieving 
comprehensive and ultrasensitive quantification of protein expression profiles within 





























Figure 1-3    Schematic of on-line integration of CIEF with nano-RPLC as a 
concentrating and multidimensional protein/peptide separation 
platform. Solid and dashed lines represent the flow paths for the 
loading of CIEF fractions and the injection of fractions into a nano-







































Compared with the coupling of strong cation exchange chromatography with 
RPLC in a multidimensional liquid chromatography system[33-37], the percentage of 
identified peptides present in more than one CIEF fraction is significantly less than that 
obtained from ion exchange chromatography fractions. A high degree of peptide overlap 
in the first dimension unnecessarily burdens the subsequent separation and greatly reduces 
the overall peak capacity in a multidimensional separation system. The presence of high 
abundance peptides in multiple fractions negatively impacts the selection of low 
abundance peptides for tandem MS identification. Additionally, the poor resolution of low 
abundance peptides adversely affects their final concentrations in the eluting peaks prior to 
MS detection. 
Besides the ultrahigh resolving power of CIEF-based multidimensional 
separations, initial proteome studies [46, 47] have supported the ability to perform 
comprehensive analysis of yeast cell lysates while requiring the amount of yeast peptides 
or proteins which are two to three orders of magnitude less than those utilized in a 
multidimensional liquid chromatography system[33-37, 49-51]. Such an increase in 
proteome sensitivity resulting from isoelectric focusing concentration and separation of 
peptides and proteins is further supported by the study of Cargile and co-workers using 
immobilized pH gradient gels[52]. By comparing with immobilized pH gradient gels[52, 
53], the significant advantages of CIEF include the ability to use higher electric fields 
resulting in rapid and ultrahigh resolution separations, improved reproducibility in 
fractions resulting from the use of gel free separation medium, and the amenability to 




avoiding potential sample loss, analyte dilution, and any post-gel peptide 
extraction/concentration procedures. 
The solubility of concentrated proteins and peptides at their pIs may become a 
problem for the CIEF separation. It should be noted that a whole family of non-detergent 
solubilizers, including glycols, sugars, and common zwitterions such as taurine, has been 
reported to greatly improve protein solubility in the proximity of their pIs[54-56], 
particularly for the analysis of membrane proteins using 2-D PAGE. These additives may 
be employed for completely preventing or largely alleviating the solubility issue, which 
may be encountered during the CIEF separation.  
1.4.2.1 Fresh frozen tissue biopsies 
Combined CIEF/nano-RPLC separations have been employed for the analysis of 
protein profiles within small and selected tumor cell populations obtained from the 
microdissection of a glioblastoma multiforme (GBM) tissue specimen[15]. By using an 
electrospray ionization (ESI)-quadrupole time-of-flight (qTOF) mass spectrometer for the 
analysis of peptides eluted from nano-RPLC (Fig. 1-4), a total of 6,866 fully tryptic 
peptides have been detected, leading to the identification of 1,820 distinct proteins with 
each corresponding to a unique human International Protein Index database entry. These  
identifications are generated from a total of 18,843 tandem mass spectra from 3 runs of a 
single GBM tissue sample, with each run consuming only 10 µg of total protein. These 

























Figure 1-4 Base peak chromatograms of a representative CIEF/nano-RPLC 
multidimensional separation of tryptic peptide digest prepared from 
microdissection-procured GBM tissue sample. Each number represents 
the sequence of CIEF fractions further analyzed by nano-RPLC from 







Furthermore, a variety of protein classes, including structural proteins, metabolic enzymes, 
receptors, and proteins involved in transcription, translation, and post-translational 
modification of gene products, are identified from the microdissection-procured GBM 
tissue samples. 
The intrinsic high resolution of CIEF allows the number of fractions sampled in 
the first separation dimension to be significantly increased for enhancing the overall peak 
capacity and dynamic range critically needed for performing comprehensive proteome 
studies. More CIEF fractions can be obtained by simply increasing the number of 
microselection valves and trap columns (Fig. 1-3), or by employing microselection valves 
with a higher number of ports. For the proteome analysis of a single GBM tissue sample, 
the number of distinct proteins identified from a single experiment of 28 CIEF fractions 
(Fig. 1-5) is comparable or slightly higher than the cumulative data set achieved using two 
runs of 14 CIEF fractions which consume twice as much sample. For the proteome 
analysis of limited tissue samples, the ability to greatly increase the overall peak capacity 
for mining deeper into the proteome can therefore be realized by simply increasing the 
number of CIEF fractions without an accompanying increase in sample consumption. By 
using computer controlled microinjection and microselection valves, the CIEF-based 


















Figure 1-5  The overlap in the proteins identified from three CIEF-nano-RPLC-
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For the identification of peptides eluted from separations, tandem MS 
instruments such as a qTOF mass spectrometer obtain peptide MS/MS spectra in a 
data-dependent way for the determination of peptide sequences. However, the data-
dependent scanning cannot acquire spectra fast enough to identify all the peptides as 
they enter the MS instrument, so many peptides and subsequent protein 
identifications are missed. The recently introduced rapid-scanning linear ion-trap 
instruments can acquire tandem mass spectra up to fifteen times faster than that using 
a qTOF mass spectrometer. By using a linear ion-trap mass spectrometer such as LTQ, 
each single proteome analysis of 10,000 enriched tumor cells yields over 10,000 
distinct and high confidence peptide hits with a false positive rate of less than 1%[57]. 
These peptide hits are further filtered by pI constraints and lead to the identification 
of more than 2,500 nonreductant proteins with greater than 80% protein overlapping 
among repeated runs of the same GBM tissue specimens.  
For peptide and protein identifications, raw LTQ data are first converted to 
peak list files. The Open Mass Spectrometry Search Algorithm (OMSSA) developed 
at the National Center for Biotechnology Information [58] is used to search the peak 
list files against a decoyed SwissProt human database. This database is constructed by 
reversing all 12,484 real sequences and appending them to the end of the sequence 
library. Searches are performed by setting up the following parameters: fully tryptic, 
1.5 Da precursor ion mass tolerance, 0.8 Da fragment ion mass tolerance, 1 missed 
cleavage, alkylated Cys as a fixed modification and variable modifications of 
acetylated N-terminus and Lys, phosphorylated Ser, Thr, and Tyr, and oxidated Met. 




Briefly, false positive rates are calculated by multiplying the number of false positive 
identifications (hits to the reversed sequences scoring below a given threshold) by 2 
and dividing by the number of total identifications. Peptides identified below 
threshold, and also occurring as matches to the forward sequences, are not counted as 
false positives or true identifications. A curve is then generated by plotting E-value 
versus false positive rate [60] and an E-value threshold corresponding to a 1% false 
positive rate is used as a cutoff[57]. 
Besides comparing normal versus GBM tissues, we have further 
investigated the differences in protein expression profiles within short-term (< 9 
months) and long-term (> 24 months) GBM survivors using a set of fresh frozen 
biopsies (n = 6 for both short- and long-term survivors) in triplicate for each specimen. 
These quantitative and comparative proteome studies using non-labeling approaches 
[61-65] have demonstrated our abilities to not only achieve high correlation within 
similar phenotypes, but also mine biomarkers across distinct phenotypes. A total of 
25 differentially expressed proteins, as indicated by a t-test score of < 0.001, can 
potentially serve as prognostic biomarkers and are being validated using additional 
tissue specimens through multiple reaction monitoring, IHC, and Western blots.  
1.4.2.2 FFPE tissues 
Because of the long history of the use of formalin as the standard fixative for 
tissue processing in histopathology, there are a large number of archival FFPE tissue 
banks worldwide. However, the high degree of covalently cross-linked proteins in FFPE 
tissues hinders efficient extraction of proteins from tissue sections and prevents 




antigens (primarily proteins) in tissue sections represents the first form of proteomics, 
wherein the ability to identify proteins is greatly enhanced by a simple and effective 
antigen retrieval (AR) technology. In the AR method, boiling the FFPE tissue sections in 
water or buffer solution dramatically reduces the detection thresholds of IHC staining 
(increasing sensitivity) for a wide range of antibodies [66-68]. This AR technique has 
revolutionized the practice of diagnostic IHC to the extent that the relevant published 
literatures of IHC are divided into “pre-AR” and “post-AR” eras[69]. In addition to the 
AR technique, a Liquid TissueTM kit has recently been developed and commercialized by 
Expression Pathology for protein extraction from FFPE tissues[45, 70].     
Besides fresh frozen tissue-based proteome studies, combined CIEF/nano-RPLC 
separations equipped with ESI-linear ion-trap MS have recently been employed to 
examine protein profiles extracted from an archival FFPE tissue of human renal carcinoma 
using the AR technique[71]. Sections of FFPE tissue are boiled in a retrieval solution of 
20 mM Tris containing 2% sodium dodecyl sulfate (SDS) for 20 min, followed by 
incubation at 60 oC for 2 hr. As a control experiment, the same FFPE tissue sample is also 
processed for AR without heating. Furthermore, fresh tissue taken from the same case of 
renal carcinoma is processed for protein extraction. Initial evaluation of the quality of 
proteins extracted from FFPE and fresh tissues is performed using SDS-PAGE. Clearly, 
protein patterns extracted from FFPE sections using the heated AR approach are 
comparable with that obtained from fresh tissue (Fig. 1-6). 
By using combined CIEF/nano-RPLC separations, tryptic peptides obtained 
from proteolytic digestion of protein extracts using the heated AR approach at pH 7 are 





















Figure 1-6 SDS-PAGE of proteins extracted from the FFPE tissue sections (Lanes 1, 
2, and 4) and comparable fresh tissue (Lane 3) of renal carcinoma. Lane 
1: heat-induced AR at pH 9. Lane 2: heat-induced AR at pH 7. Lane 4: 























Figure 1-7 Base peak chromatograms of CIEF/nano-RPLC multidimensional 
separation of tryptic peptides obtained from the FFPE human renal 
carcinoma tissue using the heat-induced AR technique. Each number 
represents the sequence of CIEF fractions further analyzed by nano-
RPLC from acid to basic pHs[71]. 
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A total of 12,855 fully tryptic peptides are identified from the FFPE tissue section treated 
with the heat-induced AR approach, leading to the identification of 3,263 distinct proteins. 
By comparing with the reported FFPE tissue-based proteome studies [45, 72, 73], our 
results present the most comprehensive analysis of human tissue proteomics including the 
identification of low abundance membrane proteins (Fig. 1-8). Again, the application of 
only single-dimension chromatography separation in these recent studies [45, 72, 73] has 
significantly limited the dynamic range and detection sensitivity of MS measurements, 
and greatly impacted their ability to mine deeper into the tissue proteome.  
Proteome results of FFPE tissue are further compared with the analysis 
performed on a fresh frozen tissue procured from the same case of renal carcinoma. More 
than 70% of proteins are identified in both tissue sections and demonstrate excellent 
correlation. Despite the potentially negative impact imparted from the FFPE process on 
protein extraction, a similar and significant amount of proteomic information can be 
retrieved from FFPE samples as compared to fresh frozen tissue specimens.  
On the other hand, a significant discrepancy in the quality of proteome results is 
found among protein extracts obtained using the heat-induced and room temperature AR 
approaches. As also demonstrated by the IHC studies [66-68], a critical element in the 
mechanism of the AR technique may be based on heat-induced modification of the three- 
dimensional structure of “formalinized” protein, restoring the condition of a formalin-





















Figure 1-8 Diagram showing the gene ontology-predicted subcellular localization 
of proteins found from the FFPE human renal carcinoma tissue using the 







In other words, the mechanism of AR technique appears to involve a re-naturation of the 
structure of fixed proteins through a series of conformational changes, including the 
possible breaking (hydrolysis) of formalin-induced cross-linkages, the entire process being 
driven by thermal energy from the heat source[67]. Still, high-temperature heating 
treatment may also induce negative results such as additional protein modifications and 
therefore requires further studies and comparisons with low-temperature heating 
treatments and combined retrieval protocols utilizing both heat and enzyme digestion [74-
76].   
1.5         INTRODUCTION TO THE THESIS 
In human disease research, where knowledge of disease outcome is critical for 
the evaluation of the significance of phenotypic or genotypic profiles, as well as response 
to therapy and outcome, it may take five, ten or more years to gain a relatively complete 
picture of the pathophysicology of a disease. The ability to analyze well-characterized 
archival cases is highly desirably. In addition, because the capacity to store large numbers 
of catalogued samples under optimal conditions is limited by cost, space and personnel 
limitations, among others, the development of technologies to analyze traditional 
pathological specimens, such as FFPE is an important priority. The experiments described 
in this thesis are designed to develop new methodologies to identify new protein 
biomarkers associated with diseased tissue. 
Still, biologically relevant proteomics data can only be generated if the tissue 
samples investigated consist of homogeneous cell populations, in which no unwanted cells 
of different types and/or development stages obscure the results. Thus, laser capture 




method for procuring homogenous subpopulations of cells for biochemical and molecular 
biological analyses. Laser microdissection involves the use of a cap coated with a thermo-
labile ethylene vinyl acetate film that is placed in contact with a stained tissue section 
visualized by an inverted microscope. A focused laser beam is then employed to produce 
localized melting of the film over selected cells such that the underlying tissue becomes 
fused to the cap and is selectively removed when the cap is lifted. 
However, in the absence of protein amplification techniques, proteomic analysis 
of microdissection-procured specimens is severely constrained by sample amounts 
ranging from 103-105 cells, corresponding to a total protein content of 0.1-10 µg[11]. 
Current proteomic techniques, included two-dimension polyacrylamide gel 
electrophoresis and shotgun-based multidimensional liquid chromatography separations, 
require substantially larger cellular samples which are generally incompatible with protein 
extract levels obtained from microdissected samples. 
Development of the capability to enable large-scale proteome studies, analogous 
to comprehensive gene expression analysis, will clearly have far-reaching impacts on 
protein biomarker investigations of human diseases such as cancer through interrogation 
of the archived FFPE tissue collections. This project therefore aims to develop and 
optimize on-line combination of Capillary Electrophoresis based separation platforms with 
nano-RPLC in an integrated platform for the comprehensive analysis of archival FFPE 
tissue specimens.  
Chapter two demonstrates the unique proteome capabilities of the CIEF-based 
multidimensional separation platform coupled with ESI-tandem MS using human salivary 




exchange chromatography utilized as the first separation dimension in multidimensional 
protein identification technology[33, 77], CIEF not only contributed to high resolving 
power together with the enrichment of low abundance proteins/peptides, but also provided 
seamless coupling with nano-RPLC while avoiding any sample loss and analyte dilution 
in an integrated platform. 
Chapter three discusses the CIEF-based proteome platform for the analysis of 
targeted tumor cells procured from microdissected fresh frozen and FFPE tissue 
specimens. Targeted proteomics research, based on the enrichment of disease-relevant 
proteins from isolated cell populations selected from high quality tissue specimens, offers 
great potential for the identification of diagnostic, prognostic, and predictive biological 
markers for use in the clinical setting and during preclinical testing and clinical trials, as 
well as for the discovery and validation of new protein drug targets. FFPE tissue 
collections, with attached clinical and outcome information, are invaluable resources for 
conducting retrospective protein biomarker investigations and performing translational 
studies of cancer and other diseases.  
By combining the antigen retrieval (AR) technique with the CIEF/Nano-RPLC 
separations, a total of 14,478 distinct peptides were identified from a single FFPE GBM 
tissue specimen. The result not only led to the identification of 2,733 non-redundant 
SwissProt protein entries, but also presented the largest catalog of proteins from a single 
microdissected FFPE tissue specimen reported to date. Protein expressions measured from 
FFPE tissue were also compared with those detected from fresh frozen specimen of the 
same, matched patient. 83% of identified FFPE tissue proteins overlapped with those 




degree of protein overlapping was attributed to the application of detergent-based protein 
extraction in both the cell pellet preparation protocol and the AR technique. This 
represents an important step forward in bringing proteomic profiling of archival FFPE 
tissues into reality. 
Chapter four evaluated the effects of length of storage period on archival tissue 
proteome analysis across ten archived uterine mesenchymal tumor tissue blocks, including 
nine uterine leiomyomas dating from 1990 to 2002 and a single case of  ASPS from 1980 
by using the capillary isotachophoresis-based proteome technology. Statistical measures, 
including the Pearson correlation coefficient and the hierarchical cluster analysis, were 
employed to evaluate the possibility of an archival effect on individual proteins or groups 
of proteins within nine leiomyomas. Low abundance proteins may be more susceptible to 
the long term storage as these proteins are more difficult to be retrieved and extracted as 
the tissue block ages in paraffin. 
Despite using tissue blocks stored for as many as 28 years, high confidence and 
comparative proteome analysis between the leiomyomas and the sarcoma was achieved. 
Though sharing over 1,800 common proteins in a core set, a total of 80 proteins unique to 
the sarcoma were identified distinguishing the ASPS from the leiomyomas. Vacuolar 
proton translocating ATPase 116 kDa subunit isoform a3, one of the unique proteins 
expressed in the ASPS, was further validated by IHC.  
Following the first medical school course in histology at Edinburgh in 1842, 
the diagnosis of cancer has come to be based upon the microscopic appearances of 
tissues (histopathology = morphologic phenotype). However, the last several decades 




protein and nucleic acid level (molecular phenotype). Thus, advanced proteome 
technologies employed and demonstrated in this study not only allow the rigorous 
evaluation of the quality and the reproducibility of proteins extracted from FFPE 
tissues for further optimization of AR methodology, but also provide significant 
opportunities in the pursuit of biomarker discovery using archived FFPE tissue 
collections. Additionally, the combination of histological criteria with advanced 
molecular analysis techniques will permit pathologists and biomedical investigators 
to incorporate alterations at the molecular level into the histological diagnosis of 
cancer, advancing the rapidly growing field of “molecular morphology”.     
The results of comparative tissue proteome studies in combination with cancer 
pathology and biology are expected to provide significant details at the global level of the 
molecular mechanisms associated with cancer. Identification of differentially expressed 
proteins that are characteristic of a clearly defined disease state paves the way for defining 
the molecular and biochemical pathways by which normal cells progress to cancerous 
states in addition to nurturing discovery of biological markers and therapeutic targets for 
cancer. The greatest expectations for targeted proteomics researched using enriched 
nonmalignant or malignant cells from high quality specimens reside in the identification of 
diagnostic, prognostic, and predictive biological markers in the clinical setting, as well as 
the discovery and validation of new protein targets in the biopharmaceutical industry. 
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2.1          INTRODUCTION 
The components contributing to the composition of whole saliva include 
salivary gland secretions, blood and other fluids such as bronchial and nasal 
secretions, and cells from the lining of the oral cavity and microflora. Saliva, and in 
particular the protein component of saliva, is involved in numerous functions 
including antimicrobial activities, digestion, enamel remineralization, and lubrication. 
Several diseases such as alcoholic cirrhosis, cardiovascular diseases, cystic fibrosis, 
diabetes mellitus, and Sjogren’s syndrome are known to directly or indirectly affect 
the functions of salivary glands[78-81]. In turn, changes in salivary composition 
correlate with disease susceptibility and/or progression. Human saliva is therefore a 




There has been growing interest in identifying “salivary biomarkers” as a 
means of monitoring general health and for the early diagnosis of diseases including 
bacterial infection, human immunodeficiency virus (HIV), and oral cancer[78, 82-85]. 
In comparison with other body fluids such as serum or urine, several further 
advantages exist in analyzing saliva including straightforward sample collection, 
sufficient quantities for analysis, and lower costs of storage and shipping. Thus, there 
is a critical need to create a periodic table of the salivary proteome that will be 
essential for the elucidation of disease pathogenesis and the evaluation of the 
influence of medications on the structure, composition, and secretion of salivary 
constituents. The salivary proteome will greatly complement the development and 
validation of the salivary-based diagnostic technologies by providing a catalog of 
salivary proteins.   
Similar to other body fluids such as serum, the large variation of protein 
relative abundances together with the complexity of the saliva proteome greatly and 
continuously challenges the development of many aspects of bioanalytical 
technologies from sample processing to separation and MS detection. Current protein 
analysis technologies are still largely based on 2-D PAGE, which has undeniably 
assumed a major role and is central to much of what is now described as 
“proteomics”. A number of research groups[86-91] have employed the 2-D PAGE-
MS technique for the analysis of whole saliva and parotid gland secretions and have 
identified some 200 proteins, likely representing a relatively small portion of the 
salivary proteome. Moreover, the application of 2-D PAGE-MS to saliva samples 




Total peak capacity improvements in multidimensional chromatography 
platforms[33, 77] have increased the number of detected peptides and proteins 
identified due to better use of the MS dynamic range and reduced discrimination 
during ionization. Based on single or multidimensional liquid chromatography, a total 
of 102 and 266 proteins were identified from human whole saliva by Wilmarth[92] 
and Hu[91], respectively. Griffin and co-workers[93] have recently combined free 
flow electrophoresis with reversed phase liquid chromatography (RPLC) for 
achieving multidimensional peptide separations and identified 437 salivary proteins. 
The overlap within their catalogs[91-93] was relatively small and included most of 
the common proteins present in high abundance and associated with housekeeping 
functions.    
As demonstrated in our previous studies for the proteome analysis of yeast 
cell lysates[46, 47]and microdissected tissue specimens[15], combined CIEF/nano-
RPLC separations have greatly enhanced the dynamic range and detection sensitivity 
of MS measurements due to high analyte concentrations in small peak volumes as the 
result of ultrahigh resolving power and electrokinetic focusing of low abundance 
proteins and peptides. CIEF, an isoelectric point (pI)-based separation, not only 
exhibits greater resolving power than that achieved in strong cation exchange 
chromatography, but also is completely orthogonal to the second dimension RPLC 
which resolves peptides based on their differences in hydrophobicity. Thus, 
CIEF/nano-RPLC separations coupled with ESI-tandem MS are employed in this 
study to address the challenges of protein complexity and protein relative abundance 




with 99% confidence from which are inferred the presence of 1,381 non-redundant 
proteins, which is the largest catalog of proteins from a single saliva sample to date.         
2.2         EXPERIMENTAL SECTION 
2.2.1 Materials and Reagents.  
Fused-silica capillaries (50 µm i.d./375 µm o.d. and 100 µm i.d./375 µm o.d.) 
were acquired from Polymicro Technologies (Phoenix, AZ). Acetic acid, ammonium 
hydroxide, dithiothreitol (DTT), iodoacetamide (IAM), and protease inhibitors were 
obtained from Sigma (St. Louis, MO). Acetonitrile, hydroxypropyl cellulose (HPC, 
average MW 100,000), tris(hydroxymethyl)aminomethane (Tris), and urea were 
purchased from Fisher Scientific (Pittsburgh, PA). Pharmalyte 3-10 was acquired 
from Amersham Pharmacia Biotech (Uppsala, Sweden). Sequencing grade trypsin 
was obtained from Promega (Madison, WI).  All solutions were prepared using water 
purified by a Nanopure II system (Dubuque, IA) and further filtered with a 0.22 mm 
membrane (Millipore, Billerica, MA). 
2.2.2 Sample Collection and Preparation.  
Whole unstimulated saliva was collected from a healthy male volunteer. 1 
mL of saliva was placed in a tube containing a mixture of protease inhibitors (1 µg 
aprotinin, 1 µg pepstatin A, and 1 µg leupeptin) and centrifuged at 20,000 g for 30 
min. The supernatant was collected and placed in a dialysis cup (Pierce, Rockford, IL) 
and dialyzed overnight at 4 °C against 100 mM Tris at pH 8.2. The protein 
concentration of the dialyzed sample was determined to be 2.3 mg/mL using the BCA 




M and 1 mg/mL, respectively, and incubated at 37 °C for 2 hr under nitrogen. IAM 
was added to a concentration of 2 mg/mL and kept at room temperature for 1 hr in the 
dark. Trypsin was added at a 1:20 (w/w) enzyme to substrate ratio and incubated 
overnight at 37 °C. The protein digest was desalted using a reversed phase trap 
column (Michrom Bioresources, Auburn, CA) and lyophilized to dryness using a 
SpeedVac (ThermoSavant, San Jose, CA), and then stored at -80 °C. 
2.2.3 Integrated CIEF/Nano-RPLC Multidimensional Separations.  
On-line coupling of CIEF with nano-RPLC as a multidimensional peptide 
and protein separation platform has been developed and described in detail in 
previous work [15, 46, 47] and was employed for systematically resolving peptide 
digests based on their differences in pI and hydrophobicity. Briefly, an 84-cm long 
CIEF capillary (100 µm i.d./365 µm o.d.)coated with hydroxypropyl cellulose was 
initially filled with a solution containing 2% pharmalyte 3-10 and 2.3 mg/mL tryptic 
peptides. Peptides were focused by applying electric field strength of 300 V/cm and 
using solutions of 0.1 M acetic acid and 0.5% ammonium hydroxide as the anolyte 
and the catholyte, respectively   
Focused peptides were sequentially fractionated by hydrodynamically 
loading into individual trap columns (3 cm x 200 µm i.d. x 365 µm o.d.) packed with 
5 -µm porous C18 reversed phase particles. Each peptide fraction was subsequently 
analyzed by nano-RPLC equipped with an Ultimate dual-quaternary pump (Dionex, 
Sunnyvale, CA) and a dual nano-flow splitter connected to two pulled-tip fused-silica 
capillaries (50 µm i.d. x 365 µm o.d.). These two 15-cm long capillaries were packed 




Nano-RPLC separations were performed in parallel in which a dual-
quaternary pump delivered two identical 2-hr organic solvent gradients with an offset 
of 1 hr. Peptides were eluted at a flow rate of 200 nL/min using a 5-45% linear 
acetonitrile gradient over 100 min with the remaining 20 min for column regeneration 
and equilibration. The peptide eluants were monitored using a linear ion-trap mass 
spectrometer (LTQ, ThermoFinnigan, San Jose, CA) operated in a data dependent 
mode. Full scans were collected from 400 - 1400 m/z and 5 data dependent MS/MS 
scans were collected with dynamic exclusion set to 30 sec. A moving stage housing 
two nano-RPLC columns was employed to provide electrical contacts for applying 
ESI voltages, and most importantly to position the columns in-line with the ESI inlet 
at each chromatography separation and data acquisition cycle.   
2.2.4 Data Analysis.  
Raw LTQ data were converted to peak list files by msn_extract.exe 
(ThermoFinnigan). OMSSA [58] was used to search the peak list files against a 
decoyed SwissProt human database. This database was constructed by reversing all 
12,484 real sequences and appending them to the end of the sequence library. 
Searches were performed by setting up the following parameters: fully tryptic, 1.5 Da 
precursor ion mass tolerance, 0.8 Da fragment ion mass tolerance, 1 missed cleavage, 
alkylated Cys as a fixed modification and variable modifications of acetylated N-
terminus and Lys, phosphorylated Ser, Thr, and Tyr, and oxidated Met. Follow-up 
searches were also performed using semi-tryptic and no enzyme specificities without 
variable modifications. Searches were run in parallel on a 12 node, 24 CPU Linux 




False positive rates were determined using the method of Elias and co-
workers[59]. Briefly, false positive rates were calculated by multiplying the number 
of false positive identifications (hits to the reversed sequences scoring below a given 
threshold) by 2 and dividing by the number of total identifications. Peptides identified 
below threshold, and also occurring as matches to the forward sequences, were not 
counted as false positives or true identifications. A curve was then generated by 
plotting E-value versus false positive rate where the definition of E-value is the 
expected number of random hits from a search library to a given spectrum that the 
random hits have an equal or better score than the hit[60]. An E-value threshold 
corresponding to a 1% false positive rate was used as a cutoff in this analysis. 
Our experience has been that OMSSA displays exceptional specificity with 
known protein mixtures and in complex proteome samples (data not shown). 
However, spectral quality, search space, and input parameters influence any scoring 
metric and therefore necessitate the application of secondary validation strategies 
which anyone can employ using any search set, algorithm, and scoring metric. In our 
hands, a decoyed database search represents one such commonly accepted option. 
After generation of search data, the result files were parsed and loaded into a custom 
MySQL database for visualization and reporting using in-house software.  
2.3         RESULTS AND DISCUSSION 
Salivary components are important determinants of oral health and essential 
in regulating the oral ecology. Alterations in the composition of the oral flora and/or 
immune dysfunction are often linked to common oral diseases[78-85]. For example, 




human parotid gland have been associated with caries[94]. Chen and co-workers have 
used MALDI-MS to compare saliva samples obtained from oral cancer patients with 
those from healthy control subjects[95]. Studying the expression of specific salivary 
proteins has demonstrated that the family of defensins exhibit antibiotic, antifungal, 
and antiviral properties[96-100]. 
2.3.1 Analysis of Tryptic Peptides Prepared from Whole Saliva.  
In this study, protein digests obtained from a single human saliva sample 
were analyzed by combined CIEF/nano-RPLC separations. In all, 29 peptide fractions 
were sampled from the first dimension CIEF separation with a total peptide loading 
of only 15.6 µg (capillary volume of 6.8 µL x peptide concentration of 2.3 mg/mL). 
Each peptide fraction was further resolved by the second dimension nano-RPLC 
separation and the eluants were detected using ESI-tandem MS. Initial search of the 
resulting MS data led to the identification of 3,642 fully tryptic peptides (at a 1% 
false positive rate), covering 1,165 distinct SwissProt protein entries. As shown in Fig. 
2-1, the search results were further compared with the most recent human saliva 
proteome reported by Xie and co-workers[93]. More than 50% of their cataloged 
saliva proteins were also identified in this study.      
In addition to a CIEF-UV trace, the number of distinct peptides and the 
distribution of the peptide’s mean pI values in each of the 29 CIEF fractions are 
further summarized in Fig. 2-2. The CIEF separation was able to cover a wide pH 















Figure 2-1 Venn diagrams comparing the proteome results obtained from this 
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Figure 2-2 Overlaid plots containing the CIEF-UV trace monitored at 280 nm, 
the number of distinct peptides identified in each of the 29 CIEF 






By comparing with immobilized pH gradient gels[52, 53], the significant advantages 
of performing pI-based separations using CIEF include the ability to use higher 
electric fields resulting in rapid and ultrahigh resolution separations and the 
amenability to automation and seamless coupling with nano-RPLC while avoiding 
any post-gel peptide extraction/ concentration procedures.  
As shown in Fig. 2-3, both the false positive rate and the numbers of distinct 
peptide and protein identifications were plotted as functions of the E-value. An E-
value of 1 by definition should indicate a 50% probability of a random match. As 
determined by a decoyed database search[59], an E-value of 1, however, returns a 
false positive rate of only 2.2%. It is likely that the actual number of possibilities for a 
random match in this case, which is defined by OMSSA as the number of MS/MS 
search queries and their fragment ion characteristics, is much less than the theoretical 
number of possibilities defined by all possible precursor ion masses for a qualifying 
peptide string within the search space and its fragment ion characteristics. An E-value 
threshold of 0.3, corresponding to 1% false positive, was therefore chosen as a cutoff 
in this study. This decoyed database search approach not only accurately reduces 
false negative identifications, but also controls the degree of false positives, while 
improving the predictive power of a typical OMSSA search. Due to the differences in 
the complexity of various proteome samples, the sample preparation procedures, the 
proteome measurements, and the search parameters, it is recommended to always 
perform a decoyed database search to determine specific score thresholds employed 





















Figure 2-3 Plots of the false positive rate and the numbers of distinct peptide 
and protein identifications versus the E-value obtained from the 
search of the peak list files against a decoyed SwissProt human 





















































In addition to the initial search for the identification of fully tryptic peptides, 
follow-up searches were performed for the detection of semi-tryptic and non-specific 
cleavages.  The results for the semi-tryptic search constitute both peptides with an 
arginine or lysine at both the N- and C-terminal cleavage sites and peptides with an 
arginine or lysine at either one of the N- or C-terminal cleavage sites. The non-
specific search results include both fully and semi-tryptic peptides as well as peptides 
which do not have an arginine or lysine at either cleavage site. As summarized in 
Table 2-1, the semi-tryptic search led to the identification of additional 1,314 peptides, 
of which 659 were semi-tryptic. The non-specific search resulted in 382 additional 
peptide identifications, of which 98 were non-tryptic. The semi-tryptic and non-
tryptic searches contributed to the identification of 135 and 81 new proteins, 
respectively. By combining the fully tryptic, semi-tryptic, and non-specific searches, 
a total of 5,338 distinct peptides were identified for the coverage of 1,381 distinct 
SwissProt protein entries, giving average protein coverage of 3.9 peptides per protein.   
In addition to performing searches against the SwissProt human database, a 
fully tryptic search was also conducted against the International Protein Index (IPI) 
human sequence database. As summarized in Table 2-2, this IPI-based search yielded 
2,422 distinct protein sequence entry matches, more than two-fold of 1,165 proteins 
identified in the SwissProt search. Of these protein identifications, only 594 proteins 
were uniquely identifiable by a peptide which is unique to the IPI database, compared 
to the 876 proteins uniquely identifiable in the SwissProt search. On the other hand, 











































18,992 3,642   3,642 3,642 1,165 1,165 
semi-
tryptic 
16,674 3,088 659  1,314 3,747 1,090 135 
non-
specific 
18,389 3,168 668 98 382 3,934 1,132 81 








































Table 2-2           Proteins Identified from Fully Tryptic Peptides at a False Positive  















SwissProt  3,642 1,165 876 115 991 













These comparisons clearly indicate that the IPI human database has a fairly large 
degree of protein sequence entry redundancy. While protein databases containing a 
large number of entries are often more comprehensive because they contain 
information for many isoforms and allele-specific translations, protein identification 
statistics cited using such databases should be examined with caution unless a 
minimization approach is employed to reduce the effects of inferring the presence of 
multiple proteins from single peptides where avoidable (i.e. Occam’s Razor).   
As shown in Table 2-2, proteins not identified by a unique peptide are 
clustered together in this study. Unique peptides are defined as distinct peptides 
which map to a single protein entry within the search database. A non-unique cluster 
can then be defined as a group of proteins which contain at least one distinct, but non-
unique peptide. This non-unique cluster approach minimized the numbers of protein 
sequence entries containing overlapping peptide sequences. The non-identical set of 
proteins can therefore be defined as the sum of the uniquely identifiable and non-
unique clusters categories. The number of proteins classified in the non-identical set 
from the two searches differed by only 4.5%, which is much less than the 2-fold 
difference observed in the number of distinct protein sequence entries and is 
comparable to the 3% difference in the distinct peptide identifications. The difference 
remaining between the non-identical set and the number of distinct protein sequence 





2.3.2 Detection of Small Proteins and Antimicrobial Proteins in Whole Saliva  
Small proteins with a molecular mass of less than 20 kDa constitute a 
characteristic portion of the human saliva proteome. A total of 241 small proteins 
were identified in the combined fully tryptic, semi-tryptic, and non-specific searches. 
After removing structural proteins and proteins commonly found in serum, histones, 
and ribosomes, 103 small proteins remained and are summarized in Table 2-3. 
Tandem MS spectra of distinct peptides leading to the identification of representative 
small proteins are presented in Fig. 2-4. 48 of these 103 small proteins are PRPs 
which are involved in creating a protective film over teeth and promoting 
remineralization of the enamel[101]. Additionally, several antimicrobial proteins 
were also identified including β-defensin 125 precursor, β-defensin 1 precursor, 
FALL-39 precursor, mucins 5B and 2, 6 different cystatin precursors, and lysozyme.  
2.3.3 Bacterial Proteins Identified in Whole Saliva 
Besides the searches against human databases, a search was also conducted 
against all of the completed bacterial genomes to identify the presence of any unique 
bacterial proteins.  This search of bacterial proteins is of particular interest as many 
species of bacterial flora colonize the oral cavity with important health implications. 
The resulting peptide hits were obtained using a rigorous score threshold at a 0.1% 
false positive rate. The identified peptide sequences were further filtered for isobaric 
matches (I↔L or K↔Q substitutions) and determined to be unique to that record 
within the NCBI non-redundant protein database. Proteins were then required to be 





Table 2-3           List of Small Proteins (< 20 kDa) Identified in Human Saliva Studies 





Thymosin β-4 (T β 4) (Fx) [Contains: 





Basic proline-rich peptide P-E (IB-9). 4 6023.7
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Small proline-rich protein 2E (SPR-2E) (Small 




Small proline-rich protein 2D (SPR-2D) 




Small proline-rich protein 2A (SPR-2A) (2-1). 2 7965.4
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Figure 2-4 Tandem MS spectra of distinct peptide hits contributing to the      
identification of representative small proteins. 
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A total of 31 bacterial species, inferred from these protein identifications, 
are summarized in Table 2-4. Some of the bacteria on the list are rare and their 
presence in a whole saliva sample is unexpected. It should be noted that some of the 
peptide sequences may map to unsequenced peptide homologs unique to other species 
or missequenced proteins in either human or bacterial proteomes. The most 
represented species was Streptococcus mutans which is the bacteria known to cause 
dental carries and is ubiquitous in the human population[84].  S. mutans was 
identified by a total of 29 proteins which contained peptides unique in the database to 
this species. In particular, the secretome of S. mutans is of great interest as the 
proteins found in whole saliva likely constitute an important part of its arsenal in 
preventing the growth of other bacteria and developing a biofilm on dental surfaces. 
Porphyromonas gingivalis, which is associated with periodontal disease, 
was identified by 4 proteins. Heliobacter pylori, which is associated with peptic ulcer 
disease and chronic gastritis, was identified by 2 proteins. Its rate of infection is 
estimated at 80% in the developed world versus 40% in the developing world. Gastric 
infection by H. pylori is currently diagnosed using techniques which rely on a biopsy 
of the gastric mucosa. Recently, it has been shown that PCR amplification of H. 
pylori DNA could be used to determine infection from both gastric mucosa biopsy 
and saliva samples of infected patients. An ELISA test is also available for the 








Table 2-4       Bacterial Species Identified by Two or More Fully Tryptic Peptide 
Sequences (False Positive Rate of 0.1%) Which Are Unique to the 
NCBI Non-Redundant Protein Database 
 
Acinetobacter sp. ADP1 
Archaeoglobus fulgidus DSM 4304 
Bacillus subtilis subsp. subtilis str.68 2 
Bdellovibrio bacteriovorus HD100 
Bordetella pertussis Tohama I 
Burkholderia mallei ATCC 23344 
Clostridium perfringens str.3 2 
Clostridium tetani E88 
Enterococcus faecalis V583 
Fusobacterium nucleatum subsp. nucleatum ATCC 25586 
Haemophilus ducreyi 35000HP 
Helicobacter pylori 26695 
Lactobacillus plantarum WCFS1 
Mesorhizobium loti MAFF303099 
Methanococcus maripaludis S2 
Methanosarcina acetivorans C2A 2 
Methylococcus capsulatus str. Bath 
Mycoplasma penetrans HF-2 
Mycoplasma pulmonis UAB CTIP 
Parachlamydia sp. UWE25 
Photobacterium profundum SS9 
Porphyromonas gingivalis W83 
Pyrobaculum aerophilum str. IM2 
Pyrococcus horikoshii OT3 
Streptococcus agalactiae NEM316 
Streptococcus mutans UA159 
Streptococcus pneumoniae TIGR4 
Streptomyces avermitilis MA-4680 
Thermoanaerobacter tengcongensis MB4 
Vibrio vulnificus YJ016 





Antibodies present in saliva against H. pylori have been examined and resulted in a 
predictive value of 45%[102]. Our saliva proteome results offer unique peptides or 
proteins which can be targeted by antibodies in the diagnosis of H. pylori infection. 
However, the relationship between gastric and oral infection remains unclear. 
2.4         CONCLUSION  
There is a growing interest in using saliva as a diagnostic fluid due to its 
relatively simple and minimally invasive collection procedures. For example, 
immunoassays targeting saliva samples have been developed for HIV, hepatitis B, 
and measles [103-105]. Saliva has also been used for hormone and drug screening 
since analyte levels in saliva are indicative of the unbound analyte concentrations [84, 
106]. However, as with any body fluids, the saliva proteome exhibits a large variation 
of protein relative abundances including high abundance proteins such as amylases, 
mucins, PRPs, and secretory IgA complex. Furthermore, salivary proteins present a 
rich array of PTMs such as glycosylation and phosphorylation which are important 
regulators of protein function [107-110]. Increasing evidence also suggests that 
proteolytic processing is another PTM of salivary proteins, illustrated by cleavages 
involving histatin family members, statherins, PRPs, and cystatins [94, 111, 112].  
By using a minimal peptide loading of only 15.6 µg, a total of 5,338 distinct 
peptides were detected at a 1% false positive rate, leading to the identification of 
1,381 distinct SwissProt protein entries from a single human saliva sample. Among 
these categorized proteins, 103 small proteins (< 20 kDa), representing a 




antimicrobial proteins such as β-defensin 125 precursor, β-defensin 1 precursor, 
FALL-39 precursor, mucins 5B and 2, 6 different cystatin precursors, and lysozyme.    
Additionally, the tandem MS spectra were searched against a database of 
completed bacterial genomes, resulting in uniquely identifiable proteins possibly 
indicating the presence of 31 bacterial species. These proteome results highlight the 
potential use of saliva for the search of diagnostic markers of human disease as well 
as exposure to common pathogens. The results further underline the need to couple 
the CIEF-based multidimensional separation platform with other sample fractionation 
techniques such as ultrafiltration [90, 91] in order to enhance the ability for mining 
deeper into the saliva proteome. In analogy to the serum proteome studies, the 
application of affinity columns to remove highly abundant salivary proteins will 
certainly play an important role in aiding the enrichment of low abundant species 
while providing more complete proteome coverage. 
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3.1         INTRODUCTION 
Because of the long history of the use of formalin as the standard fixative 
for tissue processing in histopathology, there is a large number of archival FFPE 
tissue banks worldwide. These FFPE tissue collections, with attached clinical and 
outcome information, present invaluable resources for conducting protein biomarker 
investigations. However, the high degree of covalently cross-linked proteins in FFPE 
tissues generally hinders efficient extraction of proteins, which has limited 
bioanalytical exploration of the potential information available in archival tissue 
banks. 
The ability to identify proteins within FFPE tissue specimens is greatly 
enhanced by a simple and effective antigen retrieval (AR) technology, in which 
boiling the FFPE tissue sections in water or buffer solution dramatically reduces the 




antibodies[66-68, 113]. In this context, IHC as applied to the demonstration of 
antigens (primarily proteins) in tissue sections represents a first form of protein 
analysis. The mechanism of AR appeared to involve a re-naturation of the structure of 
fixed proteins through a series of conformational changes, including the possible 
breaking (hydrolysis) of formalin-induced cross-linkages, the entire process being 
driven by thermal energy from the heat source[67, 114]. Still, the high-temperature 
heating treatment may also induce negative results such as additional protein 
modifications and therefore require further studies and comparisons with low-
temperature heating treatment and combined retrieval protocols involving heat and 
enzyme digestion[74, 75].   
Based on the principle of heat-induced AR technique, Ikeda and co-
workers[115] have extracted proteins from FFPE tissues by heating the sections in a 
radioimmunoprecipitation buffer containing 2% SDS. Subsequently, Yamashita and 
Okada[116] performed protein extraction from FFPE tissues by autoclaving the 
sections, followed by incubating the sections with a solution containing urea, 2-
mercaptoethanol, and 2% SDS. A commercial Liquid TissueTM kit apparently based 
on the same AR technique was recently introduced for processing FFPE tissues also 
in the presence of detergent while heating at 95 °C for 90 min[45, 70].     
In addition to IHC-based tissue proteome studies, current protein/peptide 
separation platforms, including 2-D PAGE and multidimensional liquid 
chromatography systems[33, 77], all require large cellular samples in order to 
increase proteomic coverage. Thus, most tissue proteomic studies have employed 




analysis of entire tissue sections instead of targeted subpopulations of 
microdissection-derived cells. However, the heterogeneous nature of most tissues, as 
well as the fact that in many cases the cells of interest may be in the minority and may 
be surrounded by normal or other abnormal cells limits the ultimate utility of whole 
tissue proteome studies in many instances. 
Several tissue microdissection technologies, including LCM [10, 11], laser 
microdissection [12], and laser-free microdissection [13, 14], have been developed to 
provide a rapid, straightforward method for procuring homogeneous subpopulations 
of cells or structures for biochemical and molecular biological analyses. However, the 
smaller quantities of ample available for microdissected populations has, to this point, 
restricted protein analyses to the use of only a single chromatography separation prior 
to tandem MS analysis and limited the ability for mining deeper into the tissue 
proteome in recent studies[42-45, 72, 73]. Since the sizes of human tissue biopsies are 
becoming significantly smaller due to the advent of minimally-invasive methods and 
early detection and treatment of lesions, a more effective discovery-based proteome 
technology is critically needed to enable sensitive studies of protein profiles that will 
have diagnostic and therapeutic relevance.    
The key to performing sensitive tissue proteome analysis, as demonstrated 
in our previous studies [15, 117], is to attain high analyte concentrations in small peak 
volumes. We have employed electrokinetic focusing and the high resolving power of 
a CIEF-based multidimensional separation platform to enhance the dynamic range 
and detection sensitivity of MS measurements. By coupling with the heat-induced AR 




separations have been demonstrated for the analysis of proteins extracted from entire 
FFPE tissue sections [71]. Instead of using whole sections, minute proteins procured 
from microdissected GBM FFPE tissues, as the model proteome system employed in 
this study, are processed, profiled, and compared with those extracted from fresh 
frozen tissues of the same, matched patient. The work reported here represents an 
important milestone toward the development, evaluation, and validation of a novel 
biomarker discovery paradigm on the basis of years of archived FFPE tissue 
collections.   
3.2         EXPERIMENTAL SECTION 
3.2.1 Clinical Materials.  
Tissues and clinical (pathological) information were obtained as part of an 
Institutional Review Board-approved study at the Cleveland Clinic. At the time of 
craniotomy, tissue samples were split equally, one portion being sent for routine 
processing in the Pathology department, the other being snap-frozen, as noted below.  
For the portion sent to pathology, from which a clinical diagnosis was made, the 
sample was processed in the routine fashion, fixed in formalin overnight, embedded 
in paraffin, and stored at room temperature after use. Approximately 6-12 months 
later, 6- m thick unstained sections were cut from this block and used for analysis, 　
as described below.  The second portion of tissue was immediately snap-frozen in 
liquid nitrogen in the operating room, embedded in the Optimal Cutting Temperature 




3.2.2 Materials and Reagents. 
Fused-silica capillaries (50 µm i.d./375 µm o.d. and 100 µm i.d./375 µm o.d.) 
were acquired from Polymicro Technologies. Acetic acid, ammonium acetate, 
ammonium hydroxide, ampholyte 3-10, DTT, formic acid, IAM, and octane were 
obtained from Sigma. Acetonitrile, hydroxypropyl cellulose (HPC, average MW 
100,000), SDS, Tris, and urea were purchased from Fisher Scientific. Sequencing 
grade trypsin was obtained from Promega (Madison, WI).  All solutions were 
prepared using water purified by a Nanopure II system (Dubuque, IA) and further 
filtered with a 0.22 mm membrane (Millipore, Billerica, MA). 
3.2.3 Tissue Microdissection and Protein Sample Preparation.  
FFPE tissues were de-paraffinized using octane, followed by vortexing and 
centrifugation [71]. Both de-paraffinized FFPE and fresh frozen tissues were 
microdissected by following the procedures described in our previous studies [13, 14] 
to gather approximately 100,000 tumor cells from each tissue specimen.  
The microdissected cells obtained from fresh frozen tissues were placed 
directly into a microcentrifuge tube containing 8 M urea and 20 mM Tris-HCl at pH 
8.0. The soluble proteins were collected in the supernatant by centrifugation at 20,000 
g for 30 min. Proteins in the supernatant were reduced and alkylated by sequentially 
adding DTT and IAM with final concentrations of 10 mg/mL and 20 mg/mL, 
respectively. The solution was incubated at 37 °C for 1 hr in the dark and then diluted 
8-fold with 100 mM ammonium acetate at pH 8.0. Trypsin was added at a 1:40 (w/w) 
enzyme to substrate ratio and the solution was incubated at 37 °C overnight. Tryptic 




Auburn, CA), lyophilized to dryness using a SpeedVac (Thermo, San Jose, CA), and 
then stored at -80 °C.  
In addition to acquiring the soluble protein fraction of targeted GBM cells 
procured from fresh frozen tissues, cell pellets were treated by a 1% SDS solution 
[118, 119] containing 20 mM Tris-HCl at pH 8.0, followed by centrifugation at 
20,000 g for 30 min. The supernatant containing the membrane protein fraction was 
placed in a dialysis cup (Pierce, Rockford, IL) and dialyzed overnight at 4 °C against 
100 mM Tris-HCl at pH 8.2. The extracted and dialyzed proteins were denatured, 
reduced, alkylated, digested, desalted, and lyophilized using the same sample 
preparation protocol as applied to the soluble protein fraction described previously. 
Similar to the procedures described in our previous studies [71], the 
microdissected GBM cells obtained from FFPE tissues were treated with a 20 mM 
Tris buffer (pH 9) containing 2% SDS, followed by heating at 100 °C on a heat block 
(VWR Scientific Products, West Chester, PA) for 20 min, then incubation at 60 °C in 
a incubator (Robbins Scientific, Sunyvale, CA) for 2 hr. The soluble proteins were 
collected in the supernatant by centrifugation at 20,000 g for 30 min. The supernatant 
was placed in a dialysis cup (Pierce) and dialyzed overnight at 4 °C against 100 mM 
Tris-HCl at pH 8.2. The extracted and dialyzed proteins were denatured, reduced, 
alkylated, digested, desalted, and lyophilized using the same sample preparation 





3.2.4 Integrated CIEF/Nano-RPLC Multidimensional Peptide Separations.  
On-line integration of CIEF with nano-RPLC as a multidimensional peptide 
and protein separation platform has been described in detail in previous work [15, 46, 
47, 117] and was employed for systematically resolving peptide digests based on their 
differences in pI and hydrophobicity. Briefly, an 80-cm long CIEF capillary (100 µm 
i.d./365 µm o.d.) coated with hydroxypropyl cellulose was initially filled with a 
solution containing 2% ampholyte 3-10 and 1.5 mg/mL tryptic peptides. Peptide 
focusing was performed by applying electric field strength of 300 V/cm and using 
solutions of 0.1 M acetic acid and 0.5% ammonium hydroxide as the anolyte and the 
catholyte, respectively. The current decreased continuously as the result of peptide 
focusing. Once the current reached ~10% of the original value, usually within 30 min, 
the focusing was considered to be complete.    
Focused peptides were sequentially fractionated by hydrodynamically 
loading into individual trap columns (3 cm x 200 µm i.d. x 365 µm o.d.) packed with 
5 µm porous C18 reversed-phase particles. A constant electric field of 300 V/cm was 
applied across the CIEF capillary for maintaining analyte band focusing in the 
capillary throughout the loading procedure. Each peptide fraction was subsequently 
analyzed by nano-RPLC equipped with an Ultimate dual-quaternary pump (Dionex, 
Sunnyvale, CA) and a dual nano-flow splitter connected to two pulled-tip fused-silica 
capillaries (50 µm i.d. x 365 µm o.d.). These two 15-cm long capillaries were packed 
with 3-µm Zorbax Stable Bond (Agilent, Palo Alto, CA) C18 particles.  
Nano-RPLC separations were performed in parallel in which a dual-




of 1 hr. Peptides were eluted at a flow rate of 200 nL/min using a 5-45% linear 
acetonitrile gradient (containing 0.02% formic acid) over 100 min with the remaining 
20 min for column regeneration and equilibration. Full scans were collected from 400 
- 1400 m/z using a linear ion-trap mass spectrometer (LTQ, ThermoFinnigan, San 
Jose, CA) and 5 data dependent MS/MS scans were gathered with dynamic exclusion 
set to 18 sec. A moving stage housing two nano-RPLC columns was employed to 
provide electrical contacts for applying electrospray voltages, and most importantly to 
position the columns in-line with the orifice of the heated metal capillary in the nano- 
ESI source at the start of each chromatography separation and data acquisition cycle. 
3.2.5 Data Analysis.  
The OMSSA developed at the National Center for Biotechnology 
Information [58] was used to search the peak list files against a decoyed SwissProt 
human database. This decoyed database was constructed by reversing all 12,484 real 
sequences and appending them to the end of the sequence library. Searches were 
performed using the following parameters: 1.5 Da precursor ion mass tolerance, 0.4 
Da fragment ion mass tolerance, 1 missed cleavage, alkylated Cys as a fixed 
modification and variable modifications of acetylated N-terminus and Lys, and 
oxidated Met. Searches were run in parallel on a 12 node, 24 CPU Linux cluster 
(Linux Networx, Bluffdale, UT). 
False positive rates were determined using the method of Elias and co-
workers[59] . Briefly, false positive rates were calculated by multiplying the number 
of false positive identifications (hits to the reversed sequences scoring below a given 




below threshold, and also occurring as matches to the forward sequences, were not 
counted as false positives or true identifications. A curve was then generated by 
plotting E-value versus false positive rate and an E-value threshold corresponding to a 
1% false positive rate was used as the cutoff in this analysis[60]. After generation of 
search data, the result files were parsed and loaded into a custom MySQL database 
for visualization and reporting using in-house software.  
3.3         RESULTS AND DISCUSSION 
In human disease research, where knowledge of disease outcome is critical 
for the evaluation of the significance of phenotypic or genotypic profiles, as well as 
response to therapy and outcome, it may take five, ten, or more years to gain a 
relatively complete picture of the pathophysiology of a disease. The ability to analyze 
well-characterized, archival cases is highly desirable.  In addition, since the capacity 
to store large numbers of catalogued samples under optimal conditions is limited by 
cost, space, and personnel limitations, among others, the development of methods to 
analyze traditional pathological specimens, such as FFPE tissues, is an important 
priority. However, too often molecular analysis techniques are applied directly to 
these formalin-paraffin materials, or extracts thereof, without an understanding of the 
variables introduced by the effects of tissue fixation and processing, whether upon the 
structure and availability of DNA, RNA, and proteins. Accessibility of 
macromolecules in the fixed tissue specimens is therefore a critical issue, exemplified 





Technological innovations already allow RNA profiling of FFPE tissues for 
the studies of patterns of altered gene expression caused by specific exposures or 
disease outcomes [120, 121]. Formalin-induced cross-linking of proteins serving as 
an efficient means of in-situ-preservation of proteins, however, greatly hinders 
efficient extraction of proteins from tissue sections and subsequent proteomic efforts. 
Building upon our initial success in the integration of the CIEF-based 
multidimensional separation platform with the AR technique[71], a selective, laser-
free microdissection approach [13, 14] is further incorporated into the workflow in 
this study to enable comprehensive analysis of protein profiles within targeted tumor 
cells instead of whole FFPE tissue blocks. 
As evaluated by SDS-PAGE (Fig. 3-1), the quality of protein pattern within 
the soluble fraction of targeted tumor cells procured from fresh frozen GBM tissue 
was superior to that extracted from microdissected FFPE tissue of the same patient. 
The smear among FFPE protein bands, particularly in the range of low - medium 
molecular masses, may be the result of protein fragmentation from the heat-induced 
AR process. Besides reinstating the condition of a formalin-modified protein back to 
its original structure, the high-temperature heating treatment has been reported to 
induce a variety of protein modifications including fragmentation [74-76].  
























Figure 3-1 Comparison of protein profiles obtained from microdissected fresh 
frozen (Lane 1) and FFPE (Lane 2) GBM tissue specimens of the 




















In addition to the evaluation of intact proteins using SDS-PAGE, combined 
CIEF/nano-RPLC separations were employed for the examination of protein digests 
to provide further in depth comparison of proteomes within microdissected fresh 
frozen and FFPE GBM tissue specimens. For profiling tryptic peptides obtained from 
a FFPE tissue sample, the entire content of focused peptides in the CIEF capillary 
was split into 19 individual fractions (Fig. 3-2) which were further resolved by nano-
RPLC and identified using nano-ESI-LTQ-MS/MS. The number of distinct peptide 
identifications measured from each CIEF fraction is significantly greater than those 
typically reported in the literature using other IEF techniques including immobilized 
pH gradient gels [52, 53] and gel-free approaches [49, 122-124] such as 
chromatofocusing, immobilized pH membranes, Rotofor, and free-flow 
electrophoresis. A key feature of our CIEF-based multidimensional separation 
technology is the elimination of protein/peptide loss and dilution in an integrated 
platform while achieving comprehensive and ultrasensitive analysis of protein 
expression profiles within FFPE tissue specimens. By contrast, preparative-scale IEF 
techniques[49, 52, 53, 122-124] are incompatible with the smaller scale of the more 
selectively-procured proteomes obtained from microdissection-procured tissues. 
As shown in Fig. 3-3, the peptide and protein false positive rates, and the 
numbers of total peptides, distinct peptides, and protein identifications were plotted as 
functions of the E-value of a typical OMSSA search. An E-value threshold of 0.17, 
corresponding to 1% false positive of total peptide identifications, was chosen as a 
cutoff in this study. A total of 14,748 distinct peptides were identified, leading to the 



















Figure 3-2 Overlaid plots containing the CIEF-UV trace monitored at 280 nm, 
the number of distinct peptides identified in each of the CIEF 
fractions, and the distribution of the peptide’s mean pI values over 














Figure 3-3  Plots of the false positive rates and the numbers of total peptide, 
distinct peptide, and distinct protein identifications versus the E-
value obtained from the search of the peak list files against a 





containing 12,484 non-redundant protein entries. This identity threshold also resulted 
in a protein false positive rate of 7.5% as indicated by the detection of peptides from 
107 distinct reversed protein sequences in the decoy section of the search database. 
The first reversed protein was detected at an E-value of 2 x 10-6. At this 
threshold score, a total of 10,755 distinct peptides were identified, leading to the 
identification of 2,224 non-redundant proteins (Fig. 3-3). By tolerating at 1% false 
positive of total peptide identifications (E-value threshold of 0.17), additional 3,993 
distinct peptides and 509 distinct proteins were measured at a cost of 112 and 107 
predicted false identifications of distinct peptides and proteins, respectively. By 
further increasing the E-value threshold to 1.3, the false positive rates escaladed to 
1.8% and 15.0% for total peptide and protein identifications, respectively.     
To better illustrate the impact of protein false positive rate on protein 
identification, it should be emphasized that new distinct proteins were added to search 
results at a ratio of approximately 50:1 relative to reversed distinct proteins at an E-
value of 2 x 10-6. At an E-value of 0.17, corresponding to a protein false positive rate 
of 7.5%, this ratio decreased to 2:1. This ratio was further reduced to 1:1 at an E-
value of 1.3, meaning that new forward protein sequences were added at a rate equal 
to that of reversed protein sequences. The implication is that all new forward protein 
sequences were likely false positives at an E-value of 1.3 which corresponded to the 
false positive rates of 1.8% and 15.0% for total peptide and protein identifications, 
respectively.   
Compared to several recently reported FFPE tissue-based proteome studies 




microdissected FFPE tissue specimen reported to date. Application of only a single-
dimension separation in these recent studies[45, 72, 73] due to sample amount 
constraints has significantly limited the dynamic range and detection sensitivity of 
MS measurements, and greatly impacted their ability to mine deeper into the tissue 
proteome. In addition to the comprehensiveness of our tissue proteome analysis, the 
percentage of overlapping proteins obtained from repeated runs of the same FFPE 
GBM tissue sample was greater than 87% as illustrated by the Venn diagram shown 
in Fig. 3-4. A total of 2,845 non-redundant proteins were identified from combined 
proteome runs of a single FFPE tissue sample.   
Among proteins identified from the microdissection-procured FFPE GBM 
tissue specimen, 488 proteins were predicted to contain at least one or more 
transmembrane domains using TMHMM (www.cbs.dtu.dk/services/TMHMM-
2.0/)[125]. The subcellular location of proteins identified from the FFPE tissue was 
assigned using the protein subcellular localization prediction tool (PSLT)[126]. Still, 
the subcellular location of approximately half of the identified proteins can not be 
assigned by PSLT. Among proteins with assigned locations, 34% were found in 
plasma membrane and organelle categories (Fig. 3-5). 
The sequence coverage of two representative transmembrane proteins, 
tenascin and basigin, is presented in Fig. 3-6 together with the examples of peptides’ 
tandem mass spectra leading to their identifications. Tenascin, a glioma-associated-
extracellular matrix antigen, is a substrate-adhesion molecule that appears to inhibit 
cell migration and may play a role in supporting the growth of epithelial tumors. 



















Figure3- 4 The overlap in the proteins identified from repeated analyses using a 


























Figure 3-5 Distribution of PSLT-predicted subcellular localization of proteins 



























































































































































































































































































































































































Figure 3-6 Peptide coverage of representative transmembrane proteins such as (A) 
tenasin and (B) basigin, and tandem MS spectra of unique peptides 





Basigin, a tumor cell-derived collagenase stimulatory factor, is enriched on the 
surface of tumor cells and up-regulated in gliomas. Its expression level correlates 
with malignant potential of the tumor[128]. For its tissue specificity, basigin is only 
present in vascular endothelium in non-neoplastic regions of the brain, whereas it is 
present in tumor cells but not in proliferating blood vessels in malignant gliomas. 
In addition to profiling the FFPE tissue proteome, combined CIEF/nano-
RPLC separations coupled with nano-ESI-LTQ-MS/MS were employed in the 
analysis of protein digests obtained from the soluble and cell pellet fractions of 
microdissected fresh frozen tissue. Fresh tissue taken from the same case of GBM 
was microdissected and processed for the extraction of soluble proteins using urea, 
followed by a SDS-based protocol [118, 119] for the preparation of membrane 
proteins from remaining cell pellets. By using a 1% false positive rate for total 
peptide identifications, a total of 2,856 and 3,227 proteins were identified from the 
soluble and pellet fractions, respectively. By combining the proteome results obtained 
from the soluble and pellet fractions, the collective analysis yielded the identification 
of 3,902 non-redundant proteins with an average of 6.2 peptides per protein, 
corresponding to 31% coverage of the SwissProt human database. 
Comparing the proteome results obtained from the fresh frozen and FFPE 
tissues (Fig. 3-7), most proteins identified from the FFPE slide were also detected in 
the corresponding fresh frozen section. Only 243 proteins, representing 8.5% of total 
protein identifications, were unique to the FFPE tissue. Among proteins identified 
from the FFPE tissue, 2,370 proteins or 83% of the total protein identifications, 





















Figure 3-7 The overlap in the proteins identified from microdissected fresh 
frozen (the soluble and pellet fractions) and FFPE GBM tissue 
specimens of the same patient using combined CIEF/nano-RPLC 






The percentage of overlap among membrane proteins (predicted to contain at least 
one or more transmembrane domains) identified from the FFPE and the pellet fraction 
of fresh frozen tissues was approximately 83% and was further increased to 88% by 
including membrane proteins measured from the soluble fraction (Fig. 3-8). We 
attribute our success with this high concordance in protein identification between 
FFPE and fresh-frozen GBM tissues to the combined effect of SDS extraction and 
heat-induced AR in concert with the exceptionally sensitive CIEF/nano-RPLC 
separations coupled with ESI-LTQ-MS/MS proteome strategy. 
3.4         CONCLUSION 
Based on the heat-induced and SDS-based AR technique, minute proteins 
extracted from the microdissection-procured FFPE GBM tissue specimen were 
processed and analyzed using combined CIEF/nano-RPLC separations coupled with 
nano-ESI-LTQ-MS/MS. By using a decoyed database search approach [59, 60], an E-
value threshold of 0.17, corresponding to 1% false positive of total peptide 
identifications, was chosen as a cutoff in this study. A total of 14,478 distinct peptides 
were therefore detected, leading to the identification of 2,733 non-redundant 
SwissProt protein entries from a single proteome analysis of microdissected FFPE 
tissue. 
Due to the ability of the CIEF-based multidimensional separation platform 
for achieving ultrahigh resolution of minute protein digests, our results present the 
largest catalog of proteins from a single microdissected FFPE tissue specimen 




















Figure 3-8 The overlap in the proteins identified from microdissected fresh 
frozen (the soluble and pellet fractions) and FFPE GBM tissue 
specimens predicted to contain at least one or more transmembrane 








By comparing with those FFPE tissue proteome studies reported recently [45, 72, 73], 
the application of only a single-dimension separation due to sample amount 
constraints has significantly limited their capability to mine deeper into the tissue 
proteome. In addition to the large proteome coverage, the reproducibility of our 
protein identifications was greater than 87% by comparing proteins identified from 
repeated runs of the same GBM tissue sample.  
A total of 2,370 FFPE tissue proteins or 83% of total protein identifications 
overlapped with those measured from the pellet fraction of fresh frozen GBM tissue 
of the same patient. This large degree of protein overlapping is the result of SDS 
extraction employed in both the cell pellet preparation protocol and the AR technique. 
The presence of SDS was critical in several AR protocols for achieving satisfactory 
protein extractions from FFPE tissue sections followed by IHC and SDS-PAGE 
analysis [66, 115, 116]. Instead of coupling high temperature heating with SDS 
treatment in a single step, a two-phase approach may be applied for protein extraction 
from the FFPE tissue in our future studies. The first phase intends to break down 
formalin-induced crosslinkings within proteins by heating. The second phase then 
involves the use of solubilization reagents such as urea and SDS for the extraction of 
the heat-retrieved proteins from the FFPE tissue.        
Following the first medical school course in histology at Edinburgh in 1842, 
the diagnosis of cancer has come to be based upon the microscopic appearances of 
tissues (histopathology = morphologic phenotype). However, the last several decades 
have seen an accumulation of data describing the characteristics of cancer cells at a 




technologies employed and demonstrated in this study not only allow the rigorous 
evaluation of the quality and the reproducibility of proteins extracted from FFPE 
tissues for further optimization of AR methodology, but also provide significant 
opportunities in the pursuit of biomarker discovery using archived FFPE tissue 
collections. Additionally, the combination of histologic criteria with advanced 
molecular analysis techniques will permit pathologists and biomedical investigators 
to incorporate alterations at the molecular level into the histological diagnosis of 
cancer, advancing the rapidly growing field of “molecular morphology”.     
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4.1          INTRODUCTION 
The criteria employed by pathologists for the diagnosis of numerous 
diseases, including essentially all cancers, have been established in formalin-fixed 
and paraffin-embedded (FFPE) tissue sections stained by hematoxylin and eosin 
(H&E). Furthermore, FFPE specimens, such as those collected under clinical trials, 
present invaluable resources for conducting retrospective investigations on molecular 
determinants associated with therapeutic response. Technological innovations already 
allow RNA profiling of FFPE sections for assessment of patterns of altered gene 
expression caused by specific exposures or disease outcomes[120, 129]. However, 
formalin-induced cross-linking of protein hinders efficient extraction of proteins from 





Boiling the FFPE tissue sections in buffer solutions dramatically reduced the 
detection thresholds of IHC staining for a wide range of antibodies in the antigen 
retrieval methodology[66-68, 114]. To increase the amounts of protein extractable 
from FFPE sections, the heat-induced antigen retrieval approach was combined with 
the application of a radioimmunoprecipitation buffer containing sodium dodecyl 
sulfate (SDS)[115] or a denaturing solution containing both urea and SDS[130]. A 
commercial Liquid TissueTM kit was introduced for processing FFPE tissues also in 
the presence of heating at 95 °C for 90 min[70]. Two recent FFPE proteome studies 
were based on the use of lysis buffers containing either guanidine hydrochloride[131] 
or organic solvent[132] at high temperature.  
Combined capillary isoelectric focusing (CIEF)/nano-reversed phase liquid 
chromatography (nano-RPLC) separations coupled with electrospray ionization-mass 
spectrometry (ESI-MS) have been demonstrated in our laboratory to enable 
ultrasensitive analysis of minute proteins extracted from whole and microdissected 
FFPE tissues[57, 71]. A capillary isotachophoresis (CITP)-based proteome platform, 
capable of providing selective analyte enrichment and high resolving power, was 
utilized in a recent study to further address the challenges of protein complexity and 
relative abundance inherent in FFPE specimens[133]. From a practical point of view, 
one of the remaining issues in performing comparative proteomic measurements 
among FFPE tissues relates to potential variability in protein composition and 
retrieval during different storage periods. Thus, the CITP proteome technology 
coupled with the spectral counting approach[63-65] is employed in this work for the 




a set of mesenchymal tumors, including nine leiomyomas dating from 1990 to 2002 
and a single vaginal alveolar soft part sarcoma (ASPS) from 1980.   
4.2          EXPERIMENTAL SECTION 
4.2.1 Materials and Reagents.  
Fused-silica capillaries (50 µm i.d./375 µm o.d. and 100 µm i.d./375 µm o.d.) 
were acquired from Polymicro Technologies (Phoenix, AZ). Acetic acid, 
dithiothreitol (DTT), formalin, iodoacetamide (IAM), and octane were obtained from 
Sigma (St. Louis, MO). Acetonitrile, ammonium acetate, hematoxylin, SDS, 
tris(hydroxymethyl)aminomethane (Tris), and urea were purchased from Fisher 
Scientific (Pittsburgh, PA). Pharmalyte 3-10 was acquired from Amersham 
Pharmacia Biotech (Uppsala, Sweden). Sequencing grade trypsin was obtained from 
Promega (Madison, WI). All solutions were prepared using water purified by a Neu-
Ion system (Baltimore, MD) equipped with a UV sterilizing lamp and a 0.05 µm 
membrane final filter. 
4.2.2 Tissue Sample Preparation. 
A blinded set of ten mesenchymal tumors were obtained from Dr. Fattaneh 
Tavassoli’s laboratory at the Yale University School of Medicine. FFPE tissues were 
de-paraffinized using octane, followed by vortexing and centrifugation[71]. Proteins 
were recovered from tissue sections of 1 cm x 1 cm x 10 µm by following heat-
induced retrieval conditions described previously[57, 71, 133]. Briefly, sections of 
fixed tissues were treated with a 20 mM Tris buffer containing 2% SDS, followed by 




20 min, then incubation at 60 0C in an incubator (Robbins Scientific, Sunyvale, CA) 
for 2 hr. The proteins collected in the supernatant were placed in a dialysis cup 
(Pierce, Rockford, IL) and dialyzed overnight at 4 0C against 100 mM Tris-HCl at pH 
8.2.  
The retrieved and dialyzed proteins were denatured, reduced, and alkylated 
by sequentially adding urea, dithiothreitol, and iodoacetamide with final 
concentrations of 8 M, 10 mg/mL, and 20 mg/mL, respectively. The solution was 
incubated at 37 0C for 1 hr in the dark and then diluted 8-fold with 100 mM 
ammonium acetate at pH 8.0. Trypsin was added at a 1:40 (w/w) enzyme-to-substrate 
ratio, and the solution was incubated at 37 0C overnight. Tryptic digests were desalted 
using a Peptide MacroTrap column (Michrom Bioresources, Auburn, CA), 
lyophilized to dryness using a SpeedVac (Thermo, San Jose, CA), and then stored at -
80 0C.    
4.2.3   Transient CITP/Capillary Zone Electrophoresis (CZE)-Based Tissue 
Proteome Analysis.  
Similar to the procedures described in our previous studies[133-135], a 80-
cm long CITP capillary (100 µm i.d./365 µm o.d.) was initially filled with a 
background electrophoresis buffer of 0.1 M acetic acid at pH 2.8. The sample 
containing protein digests retrieved and processed from FFPE tumor tissues was 
prepared in a 2% pharmalyte solution. A 50-cm long sample plug, corresponding to 
4.0 µL sample volume, was hydrodynamically injected into the capillary. A positive 
electric voltage of 24 kV was then applied to the inlet reservoir, which was filled with 




The cathodic end of the capillary was housed inside a stainless steel tube 
(460 µm i.d./785 µm o.d.) using a coaxial liquid sheath flow configuration[136]. A 
sheath liquid composed of 0.1 M acetic acid was delivered at a flow rate of 1 µL/min 
using a Harvard Apparatus 22 syringe pump (South Natick, MA). The stacked and 
resolved peptides in the CITP/CZE capillary were sequentially fractionated and 
loaded into individual wells on a moving microtiter plate. The entire capillary content 
was separated and sampled into 30 individual fractions in less than 2 hr. The CITP 
separation and fractionation apparatus was operated on an in-house built robotic 
platform controlled by LabView (National Instruments, Austin, TX).  
To couple transient CITP/CZE with nano-RPLC, peptides collected in 
individual wells were sequentially injected into dual trap columns (3 cm x 200 µm i.d. 
x 365 µm o.d.) packed with 5 µm porous C18 reversed-phase particles. Each peptide 
fraction was subsequently analyzed by nano-RPLC equipped with an Ultimate dual-
quaternary pump (Dionex, Sunnyvale, CA) and a dual nano-flow splitter connected to 
two pulled-tip fused-silica capillaries (50 µm i.d. x 365 µm o.d.). These two 15-cm 
long capillaries were packed with 3-µm Zorbax Stable Bond (Agilent, Palo Alto, CA) 
C18 particles.  
Nano-RPLC separations were performed in parallel in which a dual-
quaternary pump delivered two identical 2-hr organic solvent gradients with an offset 
of 1 hr. Peptides were eluted at a flow rate of 200 nL/min using a 5-45% linear 
acetonitrile gradient over 100 min with the remaining 20 min for column regeneration 
and equilibration. The peptide eluants were monitored using a linear ion-trap mass 




ionization interface and operated in a data dependent mode. Full scans were collected 
from 400 - 1400 m/z and 5 data dependent MS/MS scans were collected with dynamic 
exclusion set to 30 sec.  
4.2.4 MS Data Analysis.  
Raw LTQ data were converted to peak list files by msn_extract.exe 
(ThermoFinnigan). Open Mass Spectrometry Search Algorithm (OMSSA)[58] 
developed at the National Center for Biotechnology Information was used to search 
the peak list files against the UniProt sequence library (April 20, 2006) with decoyed 
sequences appended. This decoyed database was constructed by reversing all 
sequences and appending them to the end of the sequence library. Searches were 
performed using the following parameters: fully tryptic, 1.5 Da precursor ion mass 
tolerance, 0.4 Da fragment ion mass tolerance, 1 missed cleavage, alkylated Cys as a 
fixed modification and variable modification of Met oxidation. Searches were run in 
parallel on a 12 node, 24 CPU Linux cluster (Linux Networx, Bluffdale, UT).  
False discovery rates (FDRs) were determined using a target-decoy search 
strategy introduced by Elias and co-workers[59] and employed in our previous study 
for a comparative evaluation among commonly used tandem MS identification search 
algorithms[137]. Briefly, FDRs were calculated by multiplying the number of false 
positive identifications (hits to the reversed sequences scoring below a given 
threshold) by 2 and dividing by the number of total identifications. Peptides identified 
below threshold, and also occurring as matches to the forward sequences, were not 
counted as false positives or true identifications. A curve was then generated by 




for total peptide identifications was chosen as a cutoff in this study. The UniProt 
sequence library consists of entries from both SwissProt and TrEMBL. Only peptide 
hits mapping to the SwissProt subset were reported.  
4.2.5    Validation of Proteins Retrieved and Identified from FFPE Tissues 
Using IHC  
Three proteins, including actin, desmin, and progesterone receptor, were chosen 
from MS-based proteomic measurements of leiomyomas for validation using IHC. 
Vacuolar proton translocating ATPase 116 kDa subunit isoform a3 (VPP3) as one of 
candidate markers whose expression profiles distinguish ASPS from leiomyoma was 
selected for validation using IHC. Primary antibodies against actin, desmin, and 
progesterone receptor were obtained from Dako (Carpinteria, CA). The mouse primary 
antibody against VPP3 was purchased from Abcam (Cambridge, MA) and incubated with 
a dilution ratio of 1:150 at 4 0C overnight.  
The biotinylated anti-mouse immunoglobulins were employed as the link 
antibody and were incubated for 30 min. The avidin-biotin-peroxidase complex 
(Vector Laboratories, Burlingame, CA) was utilized as the labeling reagent and 
incubated for 30 min. A 10-min wash step with Tris buffered saline (TBS) was 
carried out between each step. Slides were counterstained by hematoxylin and 
mounted for examination. Negative controls were conducted using TBS instead of the 
primary antibody. Immunostained slides were evaluated by microscopy. The intensity 






4.3         RESULTS AND DISCUSSION 
Because the capacity to store large numbers of catalogued clinical fresh 
frozen samples under optimal conditions is limited by cost, space, and personnel 
limitations, it is important to explore the utility of a large number of archival FFPE 
tissue banks available worldwide for extraction of molecular data using novel 
technologies. These tissue banks particularly constitute invaluable resources for 
translational studies of cancer. In cancer research, where knowledge of disease 
outcome is critical in the evaluation of the significance of particular phenotypes or 
genotypes, and where it may take five or more years to complete expensive 
prospective studies, the ability to analyze documented archival cancer cases with 
known outcome is highly desirable.  
From the onset, it was apparent that proper sample preparation is critical in 
application of IHC to FFPE tissues[138, 139]. Shi et al.[66, 140] clearly illustrated 
that hydrolysis of cross-linkages between formalin and protein can be disrupted by 
high temperature heating. As demonstrated in our previous studies[57, 71, 133], the 
ability to achieve excellent protein recovery from FFPE tissues for shotgun proteome 
analysis was attributed to the use of both heating and use of detergents such as SDS. 
In fact, Fowler et al.[141] have compared 6 different protocols including commercial 
reagents such as Liquid TissueTM[70] for protein extraction from FFPE tissues, and 
concluded that the most effective protein extraction buffer tested is a 20 mM Tris 
solution containing 2% SDS under high temperature heating protocol[57, 71, 133].  
Following optimized protein extraction and digestion procedures for 




tissue blocks, including nine uterine leiomyomas and a single vaginal ASPS, were 
employed for performing shotgun-based tissue proteome analysis. The leiomyomas 
were categorized into three groups of three cases each by the archival year of 1990, 
1997, and 2002. The sarcoma case was collected from 1980. It was unknown to the 
analyzers that this tissue was a significantly different type of mesenchymal tumor - an  
ASPS in contrast to the benign nature of the leiomyomas that are of smooth muscle 
derivation. As shown in Fig. 4-1, the morphology revealed by H&E staining is 














































The proteomic results obtained from the CITP-based proteome platform 
were summarized in Table 4-1 for all ten mesenchymal tumor tissues examined in 
this study. The 1990 group of leiomyomas returned slightly poorer proteome 
performance compared to the leiomyomas cataloged in 1997 and 2002. There was no 
discernable difference between the 1997 and 2002 groups. The 1980 ASPS case 
yielded over 2,400 protein identifications which were near the upper end of what 
were detected for all 10 tumors, despite being the oldest FFPE tissue sample.  
By including proteins identified by at least two distinct (different) peptide 
sequences, the Venn diagram shown in Fig. 4-2 illustrates the overlap among proteins 
identified in the sarcoma (ASPS) and leiomyomas. It is not surprising that, of the 
2,583 proteins identified, 653 were found uniquely in the leiomyomas. This may be 
simply the result of the larger number of leiomyoma samples compared to a single 
example of sarcoma analyzed. The 80 proteins identified uniquely in the sarcoma 
case are significant, however, exactly because they were not discovered in the 
leiomyomas despite having evaluated nine different tumors. For example, VPP3 as 
one of unique proteins expressed in the ASPS was identified by three distinct peptides 












Table 4-1         Summary of Proteomic Results Obtained from Mesenchymal Tumor 
Tissues 
Tumor Year Spectral Counts Distinct Peptides Distinct Proteins
Sarcoma 1980 18,254 8,994 2,418 
 Leiomyoma 1990 15,193 5,887 1,714 
Leiomyoma 1990 12,556 5,599 1,593 
Leiomyoma 1990 12,976 5,064 1,707 
Leiomyoma 1997 22,267 7,897 2,138 
Leiomyoma 1997 34,810 12,413 2,671 
Leiomyoma 1997 26,235 9,259 2,227 
Leiomyoma 2002 41,711 10,020 2,406 
Leiomyoma 2002 18,134 6,852 1,977 






























Figure 4-2 The Venn diagram comparing proteins identified from the sarcoma 
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Figure 4-3 (A) Tandem MS spectrum of unique peptide 
LGALQQLQQQSQELQEVLGETER leading to the identification of 










Besides comparing identified proteins, the CITP-based proteome platform 
was coupled with the spectral counting approach[63-65] to quantify changes in 
protein expression between the ASPS and leiomyomas. The spectral counts of 
individual proteins were normalized against the total spectral counts of that run over 
the normalized total from all runs considered and termed expression values. All 
proteins with spectral counts > 1 were included in the determination of the Pearson 
correlation coefficient for the assessment of proteomic data quality and 
reproducibility.   
Great correlation among quantitative proteome results obtained from 
leiomyomas was achieved in this study. For example, correlation of any of the three 
leiomyoma groups (archived in 1990, 1997, and 2002) with any of the other two sets 
yielded a Pearson R2 value of greater than 0.97 (Fig. 4-4A). Despite correlating 
among different patient samples, this value compares favorably with a recent report 
of a Pearson R2 correlation of 0.88 for performing technical replicates of the same 
protein digest using a multidimensional liquid chromatography system[142].  
In contrast, the correlation between the vaginal sarcoma (ASPS) and the 
uterine leiomyomas was moderate, with a Pearson R2 value of 0.53 (Fig. 4-4B). 
Despite sharing over 1,800 common proteins in a core set (Fig. 4-2), significant 
differences in protein expression were clearly observed between the two tumor types. 
Based on spectral counts of identified proteins, categorization of tumor specimens 
was achieved by an unsupervised hierarchical cluster analysis[143]. As shown in Fig. 

























Figure 4-4 (A) Pearson correlation plot between 2002 and 1990 leiomyoma 
tumor groups. (B) Pearson correlation plot between 1980 sarcoma 
and 1990 leiomyoma tumor groups. 
















































It is important to rule-out the possibility of comparison bias due to sample 
archival time. From this perspective it is interesting to note that the nine leiomyomas 
do not cluster by the archival year (Fig. 4-5). Neither do they group by diagnosis or 
patient age (data not shown). Furthermore, as discussed previously, each of the three 
leiomyoma groups (archived in 1990, 1997, and 2002) strongly correlate with the 
others in quantitative proteome measurements evaluated by the Pearson coefficient 
(Fig. 4-4A). 
The expression values of three proteins, including actin, desmin, and 
progesterone receptor as commonly used markers for leiomyomas, were selected 
from proteome datasets to further investigate potential effects of archival time on the 
tissue proteome. As shown in Fig. 4-6, protein expression of these three markers was 
remarkably consistent over twelve years of archival time from 1990 to 2002. 
Representative IHC results shown in Fig. 4-7 validated MS-based proteome profiling 
of FFPE tumor tissues which were dated back as many as 18 years ago.        
The modest disparity in the expression value of markers among nine 
leiomyomas (Fig. 4-6) could easily be attributed to case-to-case variation. The mean 
coefficient of variance (CV) for all quantified proteins across the leiomyoma cases 
was determined to be 48.9%. Considering a mean analytical CV of about 15-20% due 
solely to variation in sample preparation and instrumentation performance, a CV of 
less than 50% determined from nine patient samples does not seem excessive, nor 













































Figure 4-6 Distribution of protein expression of three leiomyoma markers, 
including actin, desmin, and progesterone receptor, over the archival 




























Figure 4-7 Representative IHC staining of three leiomyoma markers, including 
(A) desmin, (B) actin, and (C) progesterone receptor, on the same 










In an attempt to evaluate the possibility of an archival effect on individual 
proteins or groups of proteins, k-means clustering was performed on all proteins 
across the average of the archival time points (Fig. 4-8). Proteins were organized into 
ten clusters with each cluster containing different range of protein abundance as 
determined by the number of spectral counts. The bottom right-hand corner of each 
panel displays the average change in protein expression with the top and bottom 
percentages for the comparisons between the 1990 and 2002 groups and among the 
1997 and 2002 cases, respectively. Expression changes in all ten clusters were 
substantially less than 2-fold and were often within the analytical variability of the 
proteome platform.  
While some individual proteins exhibited significant changes in expression 
between some cases on average, there was only modest change across time points 
consistent with an archival effect. That is, an archival effect may influence the 
retrieval of a protein or group of proteins over time and thus impact the subsequent 
proteomic measurements. Averaging the entire proteome data set for each averaged 
archival year shows an overall increase of protein expression by 23% from the 1990 
to 2002 groups. The same calculation, however, indicates almost no difference in 
protein expression among the 1997 and 2002 cases. Furthermore, the k-means cluster 
suggests that there may be an archival effect for low abundance proteins detected and 
quantified by less than ten spectral counts in which these proteins are more difficult to 
























Figure 4-8 The k-means clustering of all leiomyoma proteins over the archival 
years from 1990 to 2002 on the x-axis. Proteins in each of ten clusters 
are varied in abundance as determined by the number of spectral 





Finally, the analysis of variance (ANOVA) was performed for comparing 
each of the three archived leiomyoma groups to the others to assess data normality. 
As shown in Fig. 4-9A, each comparison showed a consistent bias toward p-values 
below 0.5. When the cases were split for a two-way comparison such that each group 
had a roughly equal mix of cases from each archival date, the comparison data 
presented a more normal distribution (Fig. 4-9B). ANOVA results shown in Figs. 4-
9A and 9B suggest that statistical comparisons across cases collected at different 
times may require the use of non-parametric methods or parametric comparisons 




































Figure 4-9 Performing ANOVA among proteomic results obtained from 
leiomyomas collected in 1990, 1997, and 2002.  (A) Two-way 
comparison between 1990 and 2002 leiomyoma tumor groups. (B) Two-
way comparison with each company containing a roughly equal mix of 




























4.4         CONCLUSION 
By coupling optimized protein extraction and digestion procedures for 
handling FFPE tissues[57, 71, 133] with the CITP-based proteome platform[134, 
135], ten archived mesenchymal tumor tissue blocks, including nine uterine 
leiomyomas dating from 1990 to 2002 and a single 1980 vaginal ASPS case, were 
employed for investigating potential effects of archival time on tissue proteome 
analysis. Although the 1990 group of leiomyomas demonstrated a slightly worse 
proteome performance in terms of total peptide, distinct peptide, and distinct protein 
identifications compared to leiomyomas cataloged in 1997 and 2002, great correlation 
among leiomyomas in quantitative proteomics was still achieved with a Pearson R2 
value of greater than 0.97 (Fig. 4-4A). Despite correlating among different patient 
samples, this value compares favorably with a recent report of a Pearson R2 
correlation of 0.88 for performing technical replicates of the same protein digest 
using a multidimensional liquid chromatography system[142].  
Besides assessing proteomic data quality and reproducibility, several 
statistical measures, including the CV, k-means clustering, and ANOVA, were used 
to evaluate the possibility of an archival effect on individual proteins or groups of 
proteins within nine leiomyomas. That is, an archival effect may influence the 
retrieval of a protein or group of proteins over time and thus impact the subsequent 
proteomic measurements. For example, averaging the entire proteome data set for 
each averaged archival year shows an overall increase of protein expression by 23% 
from the 1990 to 2002 groups. Furthermore, the k-means cluster suggests that there 




than ten spectral counts in which these proteins are more difficult to be retrieved and 
extracted as the tissue block ages. 
Still, the expression values of three commonly used leiomyoma markers, 
including actin, desmin, and progesterone receptor, were remarkably consistent over 
twelve years of archival time from 1990 to 2002 and validated using IHC 
measurements. Furthermore, high confidence and comparative proteome analysis 
between the uterine leiomyomas and the vaginal sarcoma (ASPS) was achieved using 
the sarcoma tissue block dating back as many as 28 years ago. Despite sharing over 
1,800 common proteins in a core set, a total of 80 proteins were uniquely identified in 
the sarcoma tissues. Furthermore, the single 1980 sarcoma case was well-
distinguished from the nine leiomyomas by an unsupervised hierarchical cluster 
analysis[143] even though the analyzers had no knowledge that one of the samples 
they had received was a substantially different tumor type.    
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There is increasing acceptance of the critical importance of correlating the 
morphologic features of tissue with the data obtained from various molecular analytic 
techniques. Access to archived FFPE tissue specimens via shotgun-based proteomic 
analyses may, therefore, open new avenues for both prospective and retrospective 
translational research. However, one of the remaining issues in performing comparative 
proteomic measurements among FFPE tissues relates to potential variability in protein 
composition and retrieval based on length of storage periods.  
The system which combines CIEF-based multidimensional separation system is 
evaluated using the human saliva sample secretory components as a model proteome 
system. Besides complexity, the greatest challenge facing comprehensive proteome 
analysis of saliva sample is related to the large variation of protein relative abundances, 
particularly in the identification of low abundance proteins. The combination of 
electrokinetic focusing/concentration with two highly resolving and orthogonal separation 
mechanisms in an integrated platform significantly enhances both the dynamic range and 
the detection sensitivity of MS toward the proteome analysis of microdissected tissue 
specimens. Instead of performing multiple runs of multidimensional separations, 
comparable or even better proteome results can be achieved by simply increasing the 
number of CIEF fractions due to the intrinsic high resolution nature of electrokinetic 
focusing. This unique feature is particularly important for the proteome analysis of limited 




In the absence of protein amplification techniques, current proteome platforms 
including 2-D PAGE and shotgun-based multidimensional liquid chromatography 
separations, require substantially larger cellular samples which are generally incompatible 
with protein extract levels obtained from limited tissue samples, particularly in individual 
cell populations procured using tissue microdissection techniques. Thus, the work 
involved in this project has successfully established the proteome techniques for analyzing 
protein extracts obtained from microdissected Fresh Frozen and FFPE tissue specimens. 
By using the laser-free microdissection technology, we avoid potential detrimental effects 
of chemical reagents and laser heating on sample quality and protein separation. The 
capabilities of CIEF-based multidimensional separations for performing proteome analysis 
from minute samples create new opportunities in the pursuit of biomarker discovery using 
enriched and selected cell populations procured from tissue specimens. These proteome 
technological advances combined with recently developed tissue microdissection 
techniques provide powerful tools for those seeking to gain a greater understanding at the 
global level of the cellular machinery associated with human diseases such as cancer.  
In addition to sample amount constraints imposed by current proteome 
techniques, the lack of optimized methodologies for protein extraction from FFPE 
tissues further restricts the ability to perform the proteomics analysis of archival 
tissues that exist in huge numbers. The goal of this stage of the research is to 
maximize the extent of protein recovery from FFPE tissues for subsequent 
comprehensive and comparative proteome analyses. It is will recognized that 
formalin-fixation causes major chemical changes in antigen by unknown protein cross 




whether or not the cross-linkages of protein caused by formalin-fixation are reversible. 
This work involved in comparison between Urea extraction and SDS extraction. The 
SDS detergent is a widely used to solublize protein, and of the extraction is better 
than the Urea comparison. However, SDS will interfere with subsequent Tandem 
Mass detection, so we minimize the SDS effect on Mass Spec by dialyzing SDS out.  
The evaluation of intact proteins using SDS-PAGE was conducted in this 
project, also the combined CIEF/nano-RPLC separations were employed for the 
examination of protein digests to provide further in depth comparison of proteomes 
within microdissected fresh frozen and FFPE GBM tissue specimens. OMSSA was 
used to search the peak list files against a decoyed SwissProt human database. The 
percentage of overlapping proteins obtained from repeated runs of the same FFPE 
GBM tissue sample was greater than 87%. A total of 2,845 non-redundant proteins 
were identified from comvined proteome runs of a single FFPE tissue sample. 
Comparing the proteome result obtained from the fresh frozen and FFPE tissues, most 
proteins identified from the FFPE slide were also detected in the corresponding fresh 
frozen section. 
Last part of the research optimized the protein extraction and digestion 
procedures for handing FFPE tissue blocks stored for as many as 28 years. Optimized 
protein extraction and digestion procedures for handling FFPE tissues are coupled 
with the CIEF-based proteome technology to evaluate the effects of length of storage 
period on archival tissue proteome analysis across ten archived uterine mesenchymal 




a single case of ASPS from 1980. One of the unique proteins expressed in the ASPS, 
is further validated by IHC.  
The results of comparative tissue proteome studies in combination with 
cancer pathology and biology are expected to provide significant details at the global 
level of the molecular mechanisms associated with cancer. Identification of 
differentially expressed proteins that are characteristic of a clearly defined disease 
state paves the way for defining the molecular and biochemical pathways by which 
normal cells progress to cancerous states in addition to nurturing discovery of 
biological markers and therapeutic targets for cancer. The greatest expectations for 
targeted proteomics research using enriched nonmalignant or malignant cells from 
high quality specimens reside in the identification of diagnostic, prognostic, and 
predictive biological markers in the clinical setting, as well as the discovery and 














LIST OF ABBREVIATIONS 
AR: Antigen Retrieval 
ASPS: Alveolar Soft Part Sarcoma 
CIEF: Capillary Isoelectric Focusing 
DNA: Deoxyribonucleic Acid 
DTT: Dithiothreitol 
ESI: Electrospray Ionization 
FFPE: Formalin-Fixed Paraffin-Embedded 
FDRs: False Discovery Rates 
GBM: Glioblastoma Multiforme 
H&E: Hematoxylin and Eosin 




LCM: Laser Capture Microdissection 
LTQ: Linear Ion-Trap Mass Spectrometer 
MALDI-MS: Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry 
MS: Mass Spectrometry 
nano-RPLC: nano-Reversed Phase Liquid Chromatography 
OMSSA: Open Mass Spectrometry Search Algorithm 
PCR: Polymerase Chain Reaction 




PSLT: Protein Subcellular Localization Prediction Tool 
PTMs: Post-Translational Modifications 
qTOF : quadrupole Time-Of-Flight 
RNA: Ribonucleic Acid 
RPLC: Reversed Phase Liquid Chromatography 
SDS: Sodium Dodecyl Sulfate 
SELDI-MS: surface-enhanced laser desorption/ionization-mass spectrometry 
SNP: Single Nucleotide Polymorphism 
TBS: Tris Buffered Saline 
Tris: tris(hydroxymethyl)aminomethane 
2-D PAGE: Two-Dimensional Polyacrylamide Gel Electrophoresis 
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